🔗

Mappings

MONDO

MONDO:0800453 juvenile absence epilepsy

MONDO:0800453 is the juvenile absence epilepsy concept, a child of the variable-age-onset idiopathic generalized epilepsy syndrome grouping.

👪

Inheritance

1

Polygenic susceptibility HP:0010982

JAE is highly heritable but not Mendelian. Liability is distributed across many common variants of small effect together with rarer variants in thalamocortical ion channel and GABA-A receptor subunit genes. There is no single-gene inheritance pattern to counsel on in the typical case, which is why the genetic entries here are typed as susceptibility or modifier rather than causative.

Polygenic inheritance

Show evidence (2 references)

PMID:27367160 SUPPORT Human Clinical

"Mutations in GABRG2 have been associated with simple febrile seizures and with genetic epilepsy syndromes, including childhood absence epilepsy, generalized epilepsy with febrile seizures plus, and Dravet syndrome or severe myoclonic epilepsy in infancy."

Illustrates that the same gene contributes across several generalized epilepsy syndromes rather than segregating with one, which is the hallmark of a polygenic liability architecture. Marked PARTIAL because the paper characterizes a gene, not the inheritance mode of JAE.

PMID:32227660 SUPPORT Human Clinical

"we conclude that there is limited evidence that CACNA1H is a monogenic cause of epilepsy in humans"

Evidence against a monogenic model for the leading candidate gene. Marked PARTIAL because refuting one gene's monogenic status supports, but does not by itself establish, a polygenic architecture for the syndrome.

?

Discussions and Knowledge Gaps

4

Is the generalized spike-wave discharge of juvenile absence epilepsy initiated by a thalamic pacemaker, or does it originate in cortex and merely recruit the thalamus, and does the answer change what should be considered the primary drug target?

CONTROVERSY UNDER DISCUSSION jae_thalamic_versus_cortical_ictogenesis

Attached to

pathophysiology#Aberrant GABAergic Inhibition in the Thalamic Reticular Nucleus pathophysiology#Corticothalamic Drive from Deep-Layer Cortical Neurons pathophysiology#Hypersynchronous Thalamocortical Oscillation

The classical account, and the one that motivates ethosuximide, places the pacemaker in thalamus: reticular GABAergic neurons rhythmically hyperpolarize relay cells, de-inactivating T-type calcium channels and producing the burst that becomes the EEG spike. Intracellular recordings in the GAERS rat support that reticular neurons burst in tight synchrony with the EEG spike. But a competing body of work locates initiation in cortex. Focal tetrodotoxin inactivation of facial somatosensory cortex in GAERS abolishes paroxysmal activity both locally and in the thalamic neurons connected to it, whereas inactivating a remote motor cortical region or the related thalamic nuclei does not; and deleting P/Q calcium channels from layer VI corticothalamic neurons alone is sufficient to produce spontaneous spike-wave absence seizures. A 2020 synthesis states outright that cortical rather than exclusively thalamic mechanisms drive ictogenesis and set the spike-wave frequency. This entry therefore models both arms as contributing nodes rather than asserting a single origin. The stake is practical: if ictogenesis is cortical, thalamic T-type blockade is treating a downstream amplifier rather than the initiator, which would help explain why ethosuximide controls absences but not the tonic-clonic seizures that dominate JAE morbidity. It is also worth noting that the decisive experiments are rodent genetic models of childhood-type absence, so their transfer to the peri-pubertal human syndrome is itself unestablished.

Proposed experiments

High-density MEG-EEG source localization of spike-wave onset in JAE

exp_jae_meg_eeg_onset_localization

Simultaneous high-density EEG and magnetoencephalography in drug-naive JAE patients, with source reconstruction of the first tens of milliseconds of each generalized spike-wave discharge, testing whether a reproducible cortical onset zone precedes thalamic recruitment as it does in rodent models.

Decision criterion

A consistent cortical lead over thalamic activity at discharge onset would support cortical ictogenesis in the human syndrome; simultaneous or thalamus-leading onset would support the thalamic pacemaker account.

Selective T-type calcium channel blocker trial in JAE

exp_jae_targeted_ttype_blocker_trial

Clinical trial of a selective T-type calcium channel antagonist in JAE, reporting absence and generalized tonic-clonic outcomes separately rather than pooled.

Decision criterion

Suppression of absences without effect on tonic-clonic seizures would indicate the thalamic burst mechanism is specific to the absence phenotype and not the whole syndrome; suppression of both would argue the thalamic node is upstream of the shared generalized mechanism.

Show evidence (4 references)

PMID:32437558 SUPPORT Other

"in contrast to the predominant opinion, cortical mechanisms, rather than an exclusively thalamic rhythmogenesis, are key in driving seizure ictogenesis and determining spike-wave frequency"

States the cortical position of the controversy explicitly, and acknowledges that it contradicts the prevailing view.

PMID:19276326 SUPPORT Model Organism

"This study demonstrates that SWDs in GAERS have a focal origin within the facial somatosensory cortex, which is sufficient and necessary to generate ictal activities."

The experimental basis for the cortical focus position, using targeted inactivation to establish necessity and sufficiency in a genetic rat model.

PMID:11896171 SUPPORT Model Organism

"A SWD started with a large hyperpolarization, which was independent of the preceding firing"

Evidence for the thalamic side of the controversy: reticular thalamic neurons show a stereotyped hyperpolarization at discharge onset that is not explained by their own prior firing.

+ 1 more reference

The cortical initiation focus for spike-wave discharges is established in rodent genetic models and localizes to somatosensory cortex, a region with no obvious counterpart role in human juvenile absence epilepsy. Does a discrete, anatomically stereotyped cortical focus exist in human JAE at all?

HUMAN MODEL MISMATCH OPEN jae_cortical_focus_human_translation

Attached to

pathophysiology#Corticothalamic Drive from Deep-Layer Cortical Neurons pathophysiology#Hypersynchronous Thalamocortical Oscillation

This is a translational-validity problem rather than an absence of evidence, which is why it is recorded as a human-model mismatch and not as a plain knowledge gap. Both pillars of the cortical focus argument are rodent: the WAG/Rij time-delay analysis localizing a focus to the peri-oral somatosensory cortex, and the GAERS tetrodotoxin inactivation showing that focus is necessary and sufficient. The WAG/Rij authors themselves hedged the extrapolation, writing only that analogous mechanisms may underlie human absence epilepsy. The mismatch has three parts. First, the rodent focus sits in the peri-oral somatosensory cortex, whereas human absence-epilepsy imaging implicates frontal and default-mode network structures rather than a single stereotyped sensory locus; JAE-specific structural imaging finds reduced grey matter in sensorimotor and frontal regions without identifying a discrete ictal generator. Second, the rodent models are models of childhood-onset absence, not of a peri-pubertal syndrome; nothing in them speaks to the JAE-specific features of later onset and high tonic-clonic burden. Third, if the human equivalent is a distributed network state rather than a focus, then focal interventions suggested by the rodent work, including targeted neuromodulation, do not have an obvious human target.

Proposed experiments

Search for a reproducible cortical onset zone in human generalized spike-wave

exp_human_jae_focus_search_intracranial

Analysis of intracranial or high-density scalp recordings from patients with idiopathic generalized epilepsy who have undergone invasive monitoring or dense EEG, applying the same nonlinear time-delay association methods used in the WAG/Rij rat to test whether a consistent cortical site leads the rest of the network at discharge onset.

Decision criterion

A reproducible leading cortical site across patients would establish that the rodent focus concept transfers; heterogeneous or absent leading sites would indicate the human syndrome is a distributed network disorder and that the focus model should not be carried over.

Peri-pubertal-onset absence model with tonic-clonic seizures

exp_jae_specific_rodent_model_peripubertal

Development or characterization of a rodent or other animal model in which absence seizures emerge around puberty and are accompanied by generalized tonic-clonic seizures, matching the JAE phenotype rather than the childhood absence phenotype the existing models reproduce.

Decision criterion

A model that reproduces peri-pubertal onset and tonic-clonic burden would allow the cortical-focus question to be asked for JAE specifically rather than inferred from childhood absence models.

Show evidence (3 references)

PMID:11850474 SUPPORT Model Organism

"Analogous mechanisms may underlie the pathophysiology of human absence epilepsy."

The authors' own explicitly hedged extrapolation to humans. Recorded as PARTIAL because it states a possibility rather than demonstrating the human case, which is precisely the mismatch this discussion records.

PMID:11850474 SUPPORT Model Organism

"Nonlinear association analysis revealed a consistent cortical "focus" within the peri-oral region of the somatosensory cortex."

Identifies the specific rodent anatomical locus whose human counterpart is in question.

PMID:41531116 SUPPORT Human Clinical

"Gray matter volume was reduced in sensorimotor regions and in the left inferior and middle frontal gyri in patients."

The best available human JAE structural imaging shows distributed sensorimotor and frontal change rather than a discrete generator, illustrating the gap between the rodent focus and human data. PARTIAL because structural volumetry cannot localize seizure onset.

Given that ClinGen has reclassified CACNA1H as a disputed epilepsy gene, should CACNA1H be retained in the JAE model at all, and if so on what footing?

CONTROVERSY OPEN cacna1h_disputed_gene_disease_validity

Attached to

pathophysiology#Polygenic Susceptibility to Generalized Absence Epilepsy pathophysiology#Altered Thalamic Low-Threshold Calcium Bursting

CACNA1H encodes Cav3.2, the very T-type channel that carries the thalamic low-threshold current this entry models, so the gene is mechanistically attractive. It was reported in a childhood absence epilepsy cohort in 2003 and subsequently entered commercial epilepsy gene panels. A 2020 reassessment found that no published or ClinVar CACNA1H variant would meet ACMG criteria for pathogenic or likely pathogenic, that large exome studies show no enrichment of rare or de novo CACNA1H variants in epilepsy cohorts relative to controls, and that Cacna1h knockout mice do not seize. ClinGen classified the gene-disease relationship as disputed. The residual possibility is that CACNA1H acts as a modifier rather than a monogenic cause, which is exactly what the GAERS rat suggests, where a Cacna1h variant accounts for roughly a third of the variance in seizure frequency. That choice has been made here rather than inherited from legacy panels. The gene is retained with relationship_type MODIFIER, not SUSCEPTIBILITY. The refutation of monogenic causation is carried directly as REFUTE evidence, and the surviving modifier role alongside it as PARTIAL, sourced to the GAERS observation above. Removal was rejected because Cav3.2 is the T-type channel this entry's whole thalamic-bursting mechanism runs on, so deleting it would leave that mechanism attributed to no gene at all; a demoted typing that carries both the refutation and what survived it is the more honest record. The discussion stays OPEN because the science is unsettled, not because the curation decision is. ClinGen's disputed classification stands, the modifier role rests on rodent data, and the experiments below are what would resolve it.

Proposed experiments

CACNA1H variant burden in syndrome-resolved IGE cohorts

exp_cacna1h_common_variant_burden_jae

Burden and common-variant association testing of CACNA1H in large idiopathic generalized epilepsy cohorts that are resolved to ILAE 2022 syndrome level, so that JAE is analysed separately from childhood absence epilepsy rather than pooled.

Decision criterion

A significant burden or association confined to a syndrome stratum would justify retaining CACNA1H as a susceptibility contributor; a null result across strata would justify removing it from the model.

Test of CACNA1H as a seizure-severity modifier in humans

exp_cacna1h_modifier_effect_human

Test whether CACNA1H genotype modifies seizure frequency, drug response, or age of onset among patients who already carry an established epilepsy risk background, mirroring the modifier effect observed in the GAERS rat.

Decision criterion

A reproducible genotype-severity relationship would support recuration of CACNA1H as a modifier rather than a susceptibility or causal gene.

Show evidence (2 references)

PMID:32227660 SUPPORT Human Clinical

"the current status of CACNA1H as a monogenic cause of epilepsy is controversial, highlighted by ClinGen's recent reclassification of CACNA1H as disputed"

Documents that the controversy is formally recognized by ClinGen, which is what makes this a curation decision rather than a settled fact.

PMID:32227660 SUPPORT Model Organism

"in support of Cav3.2 contributing to seizure susceptibility as a modifier"

Preserves the surviving modifier hypothesis from the same analysis that refutes the monogenic claim, which is the alternative framing this discussion asks curators to weigh.

Does the age-of-onset boundary that separates juvenile absence epilepsy from childhood absence epilepsy mark a real mechanistic discontinuity, or is it a convenient cut through a single continuous absence-epilepsy spectrum?

KNOWLEDGE GAP OPEN jae_cae_syndrome_boundary

Attached to

pathophysiology#Polygenic Susceptibility to Generalized Absence Epilepsy

The two syndromes are separated primarily by age of onset around puberty, and they share the thalamocortical mechanism, the EEG signature, and much of their candidate genetics. Yet they differ substantially in the things patients care about: absence frequency, generalized tonic-clonic burden, and the probability of remission. Nothing currently in the model explains why the same circuit lesion should produce a self-limiting pyknoleptic illness when it declares at age six and a persistent tonic-clonic-dominant illness when it declares at age twelve. Candidate explanations are different underlying genetic architecture, a pubertal endocrine or maturational modifier acting on an identical substrate, or an artefact of where the ILAE drew the line. JAE-specific imaging offers a partial handle: patients differ from controls in sensorimotor and frontal grey matter, and one trait, dorsal midcingulate volume, is shared with unaffected siblings, which suggests a heritable trait marker separable from the disease state. This gap matters for curation because it determines whether dismech should carry two mechanistically distinct entries or one entry with an onset-stratified model.

Proposed experiments

Genetic-correlation analysis between CAE and JAE

exp_cae_jae_shared_polygenic_architecture

Estimate the genetic correlation between syndrome-resolved childhood absence epilepsy and juvenile absence epilepsy cohorts, and test whether age of onset behaves as a continuous polygenic trait or as a mixture of two distinct liability distributions.

Decision criterion

A genetic correlation near unity with continuous onset liability would favour a single spectrum; distinguishable architectures would support two mechanistically separate entries.

Pubertal endocrine modifier study in absence epilepsy

exp_pubertal_modifier_absence_onset

Prospective study of children with absence epilepsy through puberty, relating pubertal staging and sex-steroid trajectories to change in absence frequency, emergence of generalized tonic-clonic seizures, and remission.

Decision criterion

If pubertal transition predicts the shift toward the JAE phenotype in children who began with a CAE phenotype, a maturational modifier acting on a shared substrate is supported over distinct diseases.

Show evidence (2 references)

PMID:35503716 SUPPORT Other

"We provide updated diagnostic criteria for these IGE syndromes determined by the expert consensus opinion of the ILAE's Task Force on Nosology and Definitions"

Establishes that the syndrome boundaries in question are set by expert consensus criteria, which is precisely why their mechanistic status is an open question rather than a measured finding.

PMID:41531116 SUPPORT Human Clinical

"increased gray matter volume in the dorsal midcingulate cortex was present in both patients and their siblings relative to controls"

Identifies a familial imaging trait present in unaffected siblings, offering a candidate endophenotype that could be tested for syndrome-specificity. PARTIAL because the study was not designed to compare JAE against childhood absence epilepsy directly.

⚙

Pathophysiology

8

Polygenic Susceptibility to Generalized Absence Epilepsy

JAE is highly heritable but, in the great majority of patients, is not monogenic. Susceptibility is conferred by common variants of individually small effect together with rarer variants in genes encoding thalamic and cortical voltage-gated calcium channels and GABA-A receptor subunits. No single gene is necessary or sufficient, and the individual gene associations that were asserted most confidently in the early literature have not all survived replication.

regulation of postsynaptic membrane potential GO:0060078 ⚠ ABNORMAL

Downstream

Altered Thalamic Low-Threshold Calcium Bursting

Aberrant GABAergic Inhibition in the Thalamic Reticular Nucleus

Show evidence (1 reference)

PMID:27367160 SUPPORT Human Clinical

"Mutations in GABRG2 have been associated with simple febrile seizures and with genetic epilepsy syndromes, including childhood absence epilepsy, generalized epilepsy with febrile seizures plus, and Dravet syndrome or severe myoclonic epilepsy in infancy."

Establishes GABA-A receptor subunit genes as a susceptibility class for generalized absence epilepsy. Marked PARTIAL because the cited spectrum is anchored on childhood absence epilepsy rather than JAE specifically.

Altered Thalamic Low-Threshold Calcium Bursting

Thalamic relay and reticular neurons carry a low-voltage-activated T-type calcium current that, when a neuron is hyperpolarized and then released, produces a low-threshold calcium spike crowned by a high-frequency burst of action potentials. This burst mode is the cellular substrate of the spike component of the spike-wave discharge, and it is the target of the first-line absence drug ethosuximide.

thalamic relay neuron CL:4023068

T-type calcium current in thalamic neurons GO:0090676 ↑ INCREASED

Downstream

Hypersynchronous Thalamocortical Oscillation

Show evidence (2 references)

PMID:11896171 SUPPORT Model Organism

"The prolonged (up to 15 action potentials), high-frequency bursts present during SWDs were tightly synchronized between adjacent neurons, correlated with the EEG spike component, and generated by a low-threshold Ca(2+) potential"

Intracellular recordings during spontaneous spike-wave discharges in the GAERS rat tie the EEG spike component directly to low-threshold calcium-generated bursts, the cellular event this node asserts.

PMID:22344687 SUPPORT Model Organism

"we identified the T-type Ca(2+) channel blockers Z941 and Z944 as candidate agents and showed in thalamic slices that they attenuated burst firing of thalamic reticular nucleus neurons in GAERS"

Pharmacological confirmation running the other direction: selectively blocking the T-type current attenuates the burst firing and suppresses absence seizures, supporting a causal rather than merely correlative role.

Aberrant GABAergic Inhibition in the Thalamic Reticular Nucleus

The thalamic reticular nucleus is a GABAergic shell that inhibits thalamic relay neurons. The rhythmic hyperpolarization it imposes is what de-inactivates T-type calcium channels in relay cells and licenses the next burst, making reticular GABAergic output the pacemaker candidate for the spike-wave rhythm. Recordings in genetic models show reticular neurons fire synchronized bursts locked to the EEG spike while retaining intranuclear lateral inhibition.

GABAergic neuron of the thalamic reticular nucleus CL:0000617

gamma-aminobutyric acid signaling pathway GO:0007214 ⚠ ABNORMAL

Downstream

Altered Thalamic Low-Threshold Calcium Bursting

Hypersynchronous Thalamocortical Oscillation

Show evidence (1 reference)

PMID:11896171 SUPPORT Model Organism

"This novel finding demonstrates that spontaneous genetically determined SWDs occur in the presence of intra-NRT lateral inhibition."

Directly characterizes reticular thalamic GABAergic behaviour during genetically determined spike-wave discharges, the claim of this node.

Corticothalamic Drive from Deep-Layer Cortical Neurons

Layer VI pyramidal neurons supply the sole descending cortical input to thalamic relay and reticular cells. Selectively removing P/Q-type calcium channels from these neurons alone is sufficient to produce a spontaneous, ethosuximide-responsive spike-wave absence phenotype, showing that the cortical arm of the loop is not merely a passive recipient of a thalamic rhythm.

layer VI corticothalamic projection neuron CL:4023013

Downstream

Hypersynchronous Thalamocortical Oscillation

Show evidence (1 reference)

PMID:26758833 SUPPORT Model Organism

"Targeted Cacna1a ablation in layer VI cells resulted in mice that display a robust spontaneous spike-wave absence seizure phenotype accompanied by behavioral arrest and inhibited by ethosuximide."

Establishes that a lesion confined to the corticothalamic arm is sufficient to generate the absence phenotype, supporting a cortical contribution to ictogenesis independent of a primary thalamic defect.

Hypersynchronous Thalamocortical Oscillation

Recurrent excitation and inhibition around the cortex-thalamus-reticular loop entrains large neuronal populations into a pathological synchronized rhythm. Network analyses in drug-naive JAE patients show the reorganization is not confined to the seizure itself: interictal network efficiency is already abnormal between seizures.

Downstream

Generalized Spike-Wave Discharges

Show evidence (3 references)

PMID:22344687 SUPPORT Other

"They arise from abnormal, hypersynchronous neuronal firing in brain thalamocortical circuits."

States the thalamocortical hypersynchrony mechanism that this node represents.

PMID:38550342 SUPPORT Human Clinical

"Compared with the resting state of the HC group, the global efficiency, local efficiency, and clustering coefficients of the JAE group decreased in the inter-ictal state."

Graph-theoretic EEG analysis in untreated JAE patients specifically, showing that network topology is abnormal even between seizures, which supports a persistent network state rather than a purely paroxysmal one.

PMID:37925871 SUPPORT Human Clinical

"We found altered dFC variability of striatal-cortical/subcortical networks in patients with JAE."

Extends the abnormal-network claim beyond the classic thalamocortical loop to striatal circuits in JAE patients. Marked PARTIAL because resting-state connectivity change is correlational and does not by itself establish that the striatum participates in generating the discharge.

Generalized Spike-Wave Discharges

Bilaterally synchronous generalized spike-wave activity is the electrographic signature of the syndrome. The ILAE places the acceptable frequency band for generalized spike-wave in the idiopathic generalized epilepsies at 2.5 to 5.5 Hz; JAE discharges are typically at the faster end of the classic 3 Hz absence rhythm.

Downstream

Absence Seizures The absence seizure is the behavioural expression of the generalized spike-wave discharge; the two are time-locked rather than merely associated.

Generalized Tonic-Clonic Seizures Generalized tonic-clonic seizures arise from the same generalized epileptic network, but the transition from spike-wave activity to a tonic-clonic seizure is not mechanistically resolved, so the edge is recorded as indirect with unknown intermediates.

Show evidence (1 reference)

PMID:35503716 SUPPORT Other

"with 2.5-5.5 Hz generalized spike-wave"

Gives the ILAE-sanctioned generalized spike-wave frequency band for the idiopathic generalized epilepsies, of which JAE is one.

Absence Seizures

Behavioral arrest with impairment of awareness, time-locked to the generalized spike-wave discharge. In JAE these are less frequent than the pyknoleptic, many-times-daily absences of childhood absence epilepsy.

Show evidence (1 reference)

PMID:22344687 SUPPORT Other

"characterized by a temporary loss of awareness, arrest of physical activity, and accompanying spike-and-wave discharges on an electroencephalogram"

Defines the clinical content of the absence seizure that this terminal node represents.

Generalized Tonic-Clonic Seizures

Most patients with JAE also have generalized tonic-clonic seizures, which distinguishes the syndrome clinically from childhood absence epilepsy and is a principal driver of the need for long-term treatment.

Show evidence (1 reference)

PMID:32644481 SUPPORT Human Clinical

"is characterized by absence seizures and generalized tonic-clonic seizures"

Establishes generalized tonic-clonic seizures as a defining component of the JAE syndrome, which is what this terminal node asserts.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Nervous System 2

Generalized Tonic-Clonic Seizures Bilateral tonic-clonic seizure with generalized onset HP:0025190

Show evidence (2 references)

PMID:32644481 SUPPORT Human Clinical

"typically starts in adolescence around puberty and is characterized by absence seizures and generalized tonic-clonic seizures"

Names generalized tonic-clonic seizures as a characteristic feature of the syndrome alongside absences.

PMID:40945312 SUPPORT Human Clinical

"the total number of generalized tonic-clonic seizures experienced, presence of absence seizures on follow-up EEG and the persistence of hyperventilation positivity on EEG were associated with an unfavorable outcome regarding seizure freedom"

A 10-year JAE follow-up cohort showing tonic-clonic seizure burden is prognostically important, supporting the clinical weight given to this phenotype.

Attention and Cognitive Impairment Attention deficit hyperactivity disorder HP:0007018

Show evidence (2 references)

PMID:32437558 SUPPORT Human Clinical

"attention deficits can be detected before the epilepsy diagnosis, may persist even when seizures are pharmacologically controlled and are aggravated by valproic acid monotherapy"

Documents the attentional comorbidity of absence epilepsy and its aggravation by valproate. Marked PARTIAL because the review addresses absence seizures broadly rather than JAE alone.

PMID:41531116 SUPPORT Human Clinical

"Gray matter volume was reduced in sensorimotor regions and in the left inferior and middle frontal gyri in patients."

Provides JAE-specific structural imaging correlates of the cognitive profile, anchoring the comorbidity claim in this syndrome rather than in absence epilepsy generally.

Other 5

Typical Absence Seizures VERY_FREQUENT HP:0011147

Onset: JUVENILE

Show evidence (2 references)

PMID:32644481 SUPPORT Human Clinical

"Juvenile absence epilepsy is an idiopathic generalized epilepsy syndrome that is recognized by the ILAE (International League Against Epilepsy) that typically starts in adolescence around puberty and is characterized by absence seizures and generalized tonic-clonic seizures."

Names absence seizures as a defining feature of the syndrome. Frequency is set VERY_FREQUENT because absence seizures are definitional for JAE, so essentially all diagnosed patients have them.

PMID:38550342 SUPPORT Human Clinical

"Thirty-six juvenile absence epilepsy (JAE) patients with a current high frequency of seizures (more than five seizures during a 2 h EEG examination) were included."

Primary-cohort documentation of recorded absence seizures in syndrome-diagnosed JAE patients, so the phenotype does not rest on a tertiary clinical reference alone.

Myoclonic Jerks OCCASIONAL Myoclonic seizure HP:0032794

Show evidence (1 reference)

PMID:32644481 SUPPORT Human Clinical

"In some patients, there may be additional myoclonic jerks as well."

States that myoclonic jerks occur in a subset of JAE patients. The qualitative phrase "in some patients" maps to OCCASIONAL under the project frequency mapping guidance.

Absence Status Epilepticus Typical absence status epilepticus HP:0032863

Show evidence (2 references)

PMID:30530409 SUPPORT Human Clinical

"AS is common in juvenile absence epilepsy"

States directly that absence status epilepticus is common in JAE. No frequency band is asserted here because this is a single case report making a qualitative claim rather than a cohort measurement.

PMID:30530409 SUPPORT Human Clinical

"An EEG disclosed, on both occasions, subcontinuous generalized spike-and-wave discharges, consistent with absence status epilepticus"

Documents the electrographic substrate of absence status, tying the phenotype to the same generalized spike-wave mechanism modelled in the pathophysiology section.

Impaired School Performance Specific learning disability HP:0001328

Show evidence (1 reference)

PMID:35595971 SUPPORT Human Clinical

"JAE had two times increased hazard for special needs education compared with age-matched population controls"

Quantifies the educational impact in a JAE-specific national registry cohort with population controls, and the same sentence records that the effect was absent in juvenile myoclonic epilepsy, which supports treating this as syndrome-specific rather than a generic epilepsy effect.

Generalized Spike-Wave on EEG EEG with spike-wave complexes HP:0010850

Show evidence (1 reference)

PMID:32644481 SUPPORT Human Clinical

"with an electroencephalographic pattern of generalized epileptiform spike and wave or polyspike and wave discharge, at times with a shifting predominance on a normal background"

Describes the generalized spike-wave EEG pattern on a normal background that characterizes the idiopathic generalized epilepsies including JAE.

🧬

Genetic Associations

2

GABRG2

Gene: GABRG2 hgnc:4087 relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (1 reference)

PMID:27367160 SUPPORT Human Clinical

"The γ-aminobutyric acid (GABAA) receptor γ2 subunit gene, GABRG2, is abundantly expressed in the mammalian brain"

Establishes GABRG2 as an epilepsy gene encoding a subunit of the principal inhibitory receptor of the brain. PARTIAL because the reported syndrome spectrum is anchored on childhood absence epilepsy rather than JAE.

CACNA1H

Gene: CACNA1H hgnc:1395 relationship_type: MODIFIER variant_origin: GERMLINE

Show evidence (2 references)

PMID:32227660 REFUTE Human Clinical

"we conclude that there is limited evidence that CACNA1H is a monogenic cause of epilepsy in humans and that this gene should be removed from commercial genetic testing panels"

Explicitly refutes CACNA1H as a monogenic epilepsy cause. Recorded as REFUTE so the entry carries the disconfirming evidence rather than an uncontested legacy association.

PMID:32227660 SUPPORT Model Organism

"in support of Cav3.2 contributing to seizure susceptibility as a modifier"

The positive evidence for the MODIFIER typing used here. From the same analysis that refutes the monogenic claim, this preserves the surviving modifier role observed in the GAERS rat. PARTIAL because the modifier effect is demonstrated in a rodent model rather than in human JAE.

💊

Medical Actions

5

Valproate

Action: Pharmacotherapy NCIT:C15986

Agent: valproic acid CHEBI:39867

Broad-spectrum antiseizure medication effective against both the absence and the generalized tonic-clonic seizures of JAE, and an independent predictor of seizure freedom in long-term follow-up. Its use is constrained by teratogenicity and by aggravation of attentional deficits, which is why it is generally avoided as first-line therapy in girls and women of childbearing potential.

Mechanism Target:

INHIBITS Hypersynchronous Thalamocortical Oscillation

Show evidence (2 references)

PMID:40945312 SUPPORT Human Clinical

"Treatment with valproate was identified as an independent predictor of a favorable outcome in terms of seizure freedom."

JAE-specific cohort evidence that valproate treatment predicts seizure freedom.

PMID:32437558 SUPPORT Human Clinical

"are aggravated by valproic acid monotherapy"

Records the cognitive cost of valproate monotherapy, which is the counterweight to its efficacy. PARTIAL because the observation is made for absence epilepsy broadly.

Ethosuximide

Action: Pharmacotherapy NCIT:C15986

Agent: ethosuximide CHEBI:4887

A T-type calcium channel blocker that acts directly on the thalamic low-threshold burst mechanism modelled in this entry. It is effective against absence seizures but does not protect against generalized tonic-clonic seizures, which limits its usefulness as monotherapy in JAE given the high tonic-clonic burden of the syndrome.

Mechanism Target:

INHIBITS Altered Thalamic Low-Threshold Calcium Bursting

Show evidence (1 reference)

PMID:26758833 SUPPORT Model Organism

"a robust spontaneous spike-wave absence seizure phenotype accompanied by behavioral arrest and inhibited by ethosuximide"

Demonstrates ethosuximide suppression of the spike-wave absence phenotype in a corticothalamic genetic model, linking the drug to the mechanism node it targets.

Lamotrigine

Action: Pharmacotherapy NCIT:C15986

Agent: lamotrigine CHEBI:6367

Broad-spectrum antiseizure medication and a preferred first-line alternative to valproate for women of childbearing age with JAE. A multicentre Bayesian comparative-effectiveness reanalysis found lamotrigine superior to levetiracetam on treatment failure and drug retention in this population.

Show evidence (1 reference)

PMID:39126356 SUPPORT Human Clinical

"Bayesian reanalysis supports LTG as first-line monotherapy for JAE in women of childbearing age, emphasizing the importance of individualized treatment strategies in women with IGE."

Directly supports lamotrigine as first-line monotherapy in the JAE subgroup where valproate is contraindicated.

Levetiracetam

Action: Pharmacotherapy NCIT:C15986

Agent: levetiracetam CHEBI:6437

Broad-spectrum antiseizure medication used in JAE, particularly where valproate is unsuitable. In the JAE-specific Bayesian comparison it underperformed lamotrigine on treatment failure and retention, although the two did not differ detectably on outright seizure freedom.

Show evidence (1 reference)

PMID:39126356 SUPPORT Human Clinical

"whereas the two ASMs did not show evident differences in terms of seizure freedom"

Supports levetiracetam as a usable option while recording that it was inferior on the primary effectiveness endpoints. PARTIAL because the evidence qualifies rather than endorses the treatment.

Selective Sodium Channel Blockers (Seizure-Aggravating)

Action: Pharmacotherapy NCIT:C15986

Agent: carbamazepine CHEBI:3387

Selective sodium channel blockers, principally carbamazepine and its relatives oxcarbazepine and phenytoin, carry a recognized risk of seizure worsening in the genetic generalized epilepsies and are generally avoided in JAE. This is modelled as a treatment entry with an aggravating rather than therapeutic target_mechanisms link so that the contraindication sits on the pathograph instead of floating free as a warning. Scope of the evidence. The cited cohort covers selective sodium channel blockers only, and its observed aggravation was significantly associated with juvenile myoclonic epilepsy rather than with JAE, so the edge is recorded against the shared generalized hypersynchrony node rather than against a JAE-specific mechanism. Not evidenced here. The GABA-elevating agents vigabatrin and tiagabine, and the gabapentinoids, are also classically listed as absence-aggravating, and the usual mechanistic account is that raising thalamic GABA tone increases GABA-B-mediated hyperpolarization of relay neurons, de-inactivating T-type calcium channels and licensing more burst firing. That account is biologically continuous with the mechanism this entry models, but no citable source for it was located in this curation pass, so it is stated here as background rather than curated as an evidenced mechanism edge.

Mechanism Target:

ACTIVATES Hypersynchronous Thalamocortical Oscillation — Recorded as ACTIVATES to make the direction of harm explicit: these agents can worsen rather than suppress generalized seizures. The target is the shared hypersynchrony node rather than a specific channel or receptor node, because the cited evidence reports clinical seizure worsening in genetic generalized epilepsy without identifying the molecular step responsible.

Show evidence (2 references)

PMID:34314016 SUPPORT Human Clinical

"Selective sodium channel blockers (SSCBs) have a limited use in genetic generalized epilepsy (GGE), due to their well-known risk of seizure worsening."

States the seizure-worsening risk that motivates treating these agents as contraindicated in the genetic generalized epilepsies, of which JAE is one.

PMID:34314016 SUPPORT Human Clinical

"Seizure worsening was reported in 5/56 patients"

Quantifies observed aggravation in a genetic generalized epilepsy cohort. Marked PARTIAL because the cohort is mixed-syndrome and the aggravation was significantly associated with juvenile myoclonic epilepsy rather than with JAE specifically, so the figure bounds rather than measures the JAE risk.

🔬

Diagnosis

2

Hyperventilation-activated EEG

Routine EEG with a standardized period of hyperventilation is the highest-yield single test. Hyperventilation reliably provokes generalized spike-wave activity and often a clinical absence in untreated patients, which converts an intermittent history into a recorded event. Persistence of hyperventilation positivity on follow-up EEG carries prognostic weight, being associated with a lower chance of seizure freedom.

Electroencephalography NCIT:C38054

Results: Bilaterally synchronous generalized spike-wave discharges on a normal background, frequently with a clinical absence during hyperventilation.

Show evidence (1 reference)

PMID:40945312 SUPPORT Human Clinical

"the persistence of hyperventilation positivity on EEG were associated with an unfavorable outcome regarding seizure freedom"

Establishes hyperventilation EEG activation as a used and prognostically informative element of JAE assessment.

Paired CSF and plasma glucose for GLUT1 deficiency

Because GLUT1 deficiency can present as absence epilepsy and is treatable with the ketogenic diet, a low CSF-to-plasma glucose ratio on paired fasting samples, followed by SLC2A1 testing, is the mechanism-directed screening step. The yield is highest in early-onset absence epilepsy but the familial form has widely variable onset, so it remains worth considering in atypical or treatment-refractory presentations.

paired fasting CSF and plasma glucose measurement

Results: A reduced CSF-to-plasma glucose ratio supports GLUT1 deficiency and prompts SLC2A1 sequencing and deletion analysis.

Show evidence (1 reference)

PMID:23106342 SUPPORT Human Clinical

"Given the major treatment and genetic counseling implications, this study confirms that SLC2A1 mutational"

States the treatment and counselling rationale that justifies screening for GLUT1 deficiency in absence epilepsy.

📈

Progression

1

Persistence into adulthood with attempted medication withdrawal

Age: Adolescence to adulthood

In contrast to childhood absence epilepsy, JAE usually persists. In a 10-year follow-up cohort, about two thirds of patients reached at least two years of seizure freedom on medication, and roughly half attempted medication withdrawal, but only a small number ultimately discontinued treatment entirely. EEG abnormalities improved over follow-up in most patients.

Show evidence (2 references)

PMID:40945312 SUPPORT Human Clinical

"Among these patients, 38 (65.5 %) achieved seizure freedom for at least 2 years."

Quantifies the seizure-freedom rate in a JAE-specific long-term cohort.

PMID:40945312 SUPPORT Human Clinical

"After a median EEG follow-up period of 6 years, abnormal EEG improved in 34 of the 58 patients"

Documents EEG improvement over long-term follow-up, supporting the electrographic component of the progression claim.

📊

Prevalence

1

Idiopathic generalized epilepsy clinic populations

Unknown Rare

JAE is one of the four ILAE idiopathic generalized epilepsy syndromes; the IGEs together account for roughly 20 to 40 percent of all epilepsies, with JAE the least common of the absence syndromes. Syndrome-specific population-based incidence estimates are not well established, so no normalized rate is asserted here.

Show evidence (1 reference)

PMID:32644481 SUPPORT Human Clinical

"Idiopathic generalized epilepsy is a group of epilepsies accounting for about 20 to 40% of all epilepsies."

Gives the share of epilepsy attributable to the IGE group as a whole. Marked PARTIAL because it bounds rather than measures JAE specifically, which is why no rate_per_100000 is asserted.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Juvenile Absence Epilepsy:

Childhood Absence Epilepsy MONDO:0010826

Overlapping Features The nearest neighbour of JAE and the hardest to separate, because the two share the thalamocortical mechanism, the EEG signature, and much of their candidate genetics. The age-of-onset boundary between them is a curation-relevant open question, recorded in the discussions block.

Distinguishing Features

Earlier onset, typically in mid-childhood rather than around puberty.
Pyknoleptic absences occurring many times daily rather than sporadically.
Much lower burden of generalized tonic-clonic seizures.
High rate of spontaneous remission, whereas JAE usually persists.

Show evidence (1 reference)

PMID:35503716 SUPPORT Other

"The goal of this paper is to delineate the four syndromes comprising the IGEs, namely childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic seizures alone."

Establishes that the ILAE treats childhood absence epilepsy and juvenile absence epilepsy as separate syndromes requiring differentiation, which is what makes this a differential rather than a synonym.

Juvenile Myoclonic Epilepsy MONDO:0009696

Overlapping Features Overlaps with JAE in age of onset and in the occurrence of absences, myoclonus, and generalized tonic-clonic seizures, but is defined by prominent myoclonic jerks, characteristically on awakening. The two syndromes also diverge on measured outcomes rather than only on semiology.

Distinguishing Features

Prominent myoclonic jerks, typically on awakening, are definitional.
Absence seizures are not required for the diagnosis.
Functional and structural imaging reorganization patterns differ from JAE.
The doubled hazard for special-needs education seen in JAE is not seen here.

Show evidence (1 reference)

PMID:35595971 SUPPORT Human Clinical

"JAE had two times increased hazard for special needs education compared with age-matched population controls (hazard ratio 2.2, 95% CI = 1.1‒4.6, p = 0.03); this was not seen in JME."

Provides a measured outcome difference between the two syndromes rather than a purely semiological distinction, supporting their separation.

Epilepsy with Generalized Tonic-Clonic Seizures Alone

Overlapping Features The fourth ILAE idiopathic generalized epilepsy syndrome. Shares the generalized spike-wave EEG and the adolescent onset but lacks absence seizures as a defining feature. No MONDO binding is asserted here because no MONDO term for this ILAE 2022 syndrome was resolvable at curation time.

Distinguishing Features

Absence seizures are absent, whereas they are definitional for JAE.
Generalized tonic-clonic seizures are the sole seizure type.

Show evidence (1 reference)

PMID:35503716 SUPPORT Other

"juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic seizures alone"

Names this syndrome as one of the four ILAE idiopathic generalized epilepsies that must be distinguished from JAE.

GLUT1 Deficiency MONDO:0011724

Overlapping Features SLC2A1 loss of function impairs glucose transport across the blood-brain barrier, and the resulting cerebral energy deficit can present as absence epilepsy that phenocopies an idiopathic generalized syndrome. It is modelled here as a differential rather than as a cause of JAE because the mechanism is metabolic rather than a thalamocortical channel or receptor defect, and because the published yield comes from early-onset absence cohorts, before age four, rather than from JAE-diagnosed patients. The familial form nevertheless has widely variable onset, so it stays on the differential list for atypical or refractory presentations. This is the one differential that changes management, since the ketogenic diet supplies ketone bodies as an alternative fuel that bypasses the missing transporter. The diet is deliberately not listed under this entry's treatments, because it treats this differential rather than JAE itself and no JAE-specific evidence for it was found in this curation pass.

Distinguishing Features

Reduced CSF-to-plasma glucose ratio on paired fasting samples.
Pathogenic SLC2A1 variant, often autosomal dominant and familial.
Paroxysmal exertional dyskinesia in some affected family members.
Onset typically before four years of age in the screened cohorts.
Responsive to the ketogenic diet, unlike polygenic JAE.

Show evidence (2 references)

PMID:23106342 SUPPORT Human Clinical

"Over both studies, 11 (12%) of 89 probands with EOAE have GLUT1 deficiency."

Quantifies the yield of SLC2A1 testing in early-onset absence epilepsy, establishing GLUT1 deficiency as a non-trivial share of absence presentations and therefore a differential worth screening for.

PMID:20574033 SUPPORT Human Clinical

"Familial glucose transporter type 1 (GLUT1) deficiency due to autosomal dominant inheritance of SLC2A1 mutations is associated with paroxysmal exertional dyskinesia; epilepsy and intellectual disability occur in some family members."

Establishes the autosomal dominant familial form and its extra-epileptic features, which are the clinical handles that separate it from polygenic JAE.

🔬

Clinical Trials

1

NCT04666610 PHASE_II

N01269, a randomized, double-blind, placebo-controlled adaptive phase 2/3 trial of brivaracetam monotherapy in patients aged 2 to 25 years with childhood or juvenile absence epilepsy. It is one of the few interventional trials that enrolls JAE as a named syndrome rather than folding it into undifferentiated generalized epilepsy.

Target Phenotypes: Typical absence seizure HP:0011147

Show evidence (1 reference)

PMID:35844134 SUPPORT Human Clinical

"We report the innovative adaptive design of an ongoing phase 2/3 trial to evaluate efficacy, safety, and tolerability of brivaracetam (BRV) monotherapy in patients 2-25 years of age with CAE or JAE."

Describes the trial and confirms that JAE is an enrolled population, which is why it is recorded here rather than only under childhood absence epilepsy.

{ }

Source YAML

click to show

name: Juvenile Absence Epilepsy
creation_date: "2026-08-04T00:00:00Z"
category: Complex
description: >-
  Juvenile absence epilepsy (JAE) is one of the four idiopathic generalized
  epilepsy syndromes recognized by the ILAE, with onset around puberty. Absence
  seizures are the defining seizure type but occur far less frequently than in
  childhood absence epilepsy, and the great majority of patients also develop
  generalized tonic-clonic seizures; a minority have myoclonic jerks. The EEG
  signature is bilaterally synchronous generalized spike-wave activity. The
  mechanism is a heritable derangement of the thalamocortical loop that permits
  pathological hypersynchronous oscillation; where in that loop the seizure is
  actually initiated is an active controversy. Unlike childhood absence epilepsy,
  JAE seldom remits spontaneously and most patients need long-term antiseizure
  medication.
parents:
  - Epilepsy
  - Neurological Disease
synonyms:
  - JAE
  - epilepsy juvenile absence
disease_term:
  preferred_term: juvenile absence epilepsy
  term:
    id: MONDO:0800453
    label: juvenile absence epilepsy
mappings:
  mondo_mappings:
    - term:
        id: MONDO:0800453
        label: juvenile absence epilepsy
      mapping_predicate: skos:exactMatch
      mapping_source: MONDO
      mapping_justification: >-
        MONDO:0800453 is the juvenile absence epilepsy concept, a child of the
        variable-age-onset idiopathic generalized epilepsy syndrome grouping.
references:
  - reference: PMID:35503716
    title: >-
      ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position
      statement by the ILAE Task Force on Nosology and Definitions.
  - reference: PMID:32437558
    title: >-
      Clinical and experimental insight into pathophysiology, comorbidity and
      therapy of absence seizures.
notes: >-
  Scope note. This entry models JAE as a distinct ILAE syndrome rather than as a
  late-onset variant of childhood absence epilepsy. The shared thalamocortical
  machinery is deliberately curated here rather than delegated to the sibling
  Childhood_Absence_Epilepsy entry, because the two syndromes differ in the
  features that matter clinically, namely absence frequency, the burden of
  generalized tonic-clonic seizures, and the likelihood of remission. Whether
  that clinical difference reflects a genuine mechanistic boundary is captured as
  an explicit open question in the discussions block rather than asserted.

  Module conformance note. Five nodes declare conformance to
  epilepsy_excitation_inhibition_imbalance. One edge deliberately departs from
  the generic module: the module runs ion-channel dysfunction into
  excitation-inhibition imbalance, whereas in the thalamocortical absence
  mechanism the arrow also runs the other way, because GABA-B-mediated
  hyperpolarization from the reticular nucleus is what de-inactivates the T-type
  calcium channels and licenses the next burst. The JAE graph therefore carries
  a reticular-to-calcium edge the module does not, which is a genuine feature of
  absence physiology rather than a conformance defect.
inheritance:
  - name: Polygenic susceptibility
    description: >-
      JAE is highly heritable but not Mendelian. Liability is distributed across
      many common variants of small effect together with rarer variants in
      thalamocortical ion channel and GABA-A receptor subunit genes. There is no
      single-gene inheritance pattern to counsel on in the typical case, which is
      why the genetic entries here are typed as susceptibility or modifier rather
      than causative.
    inheritance_term:
      preferred_term: Polygenic inheritance
      term:
        id: HP:0010982
        label: Polygenic inheritance
    evidence:
      - reference: PMID:27367160
        reference_title: >-
          Molecular Pathogenic Basis for GABRG2 Mutations Associated With a
          Spectrum of Epilepsy Syndromes, From Generalized Absence Epilepsy to
          Dravet Syndrome.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Mutations in GABRG2 have been associated with simple febrile seizures
          and with genetic epilepsy syndromes, including childhood absence
          epilepsy, generalized epilepsy with febrile seizures plus, and Dravet
          syndrome or severe myoclonic epilepsy in infancy.
        explanation: >-
          Illustrates that the same gene contributes across several generalized
          epilepsy syndromes rather than segregating with one, which is the
          hallmark of a polygenic liability architecture. Marked PARTIAL because
          the paper characterizes a gene, not the inheritance mode of JAE.
      - reference: PMID:32227660
        reference_title: CACNA1H variants are not a cause of monogenic epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          we conclude that there is limited evidence that CACNA1H is a monogenic
          cause of epilepsy in humans
        explanation: >-
          Evidence against a monogenic model for the leading candidate gene. Marked
          PARTIAL because refuting one gene's monogenic status supports, but does
          not by itself establish, a polygenic architecture for the syndrome.
pathophysiology:
  - name: Polygenic Susceptibility to Generalized Absence Epilepsy
    biological_scale: MOLECULAR
    description: >-
      JAE is highly heritable but, in the great majority of patients, is not
      monogenic. Susceptibility is conferred by common variants of individually
      small effect together with rarer variants in genes encoding thalamic and
      cortical voltage-gated calcium channels and GABA-A receptor subunits. No
      single gene is necessary or sufficient, and the individual gene
      associations that were asserted most confidently in the early literature
      have not all survived replication.
    biological_processes:
      - preferred_term: regulation of postsynaptic membrane potential
        term:
          id: GO:0060078
          label: regulation of postsynaptic membrane potential
        modifier: ABNORMAL
    downstream:
      - target: Altered Thalamic Low-Threshold Calcium Bursting
      - target: Aberrant GABAergic Inhibition in the Thalamic Reticular Nucleus
    evidence:
      - reference: PMID:27367160
        reference_title: >-
          Molecular Pathogenic Basis for GABRG2 Mutations Associated With a
          Spectrum of Epilepsy Syndromes, From Generalized Absence Epilepsy to
          Dravet Syndrome.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Mutations in GABRG2 have been associated with simple febrile seizures
          and with genetic epilepsy syndromes, including childhood absence
          epilepsy, generalized epilepsy with febrile seizures plus, and Dravet
          syndrome or severe myoclonic epilepsy in infancy.
        explanation: >-
          Establishes GABA-A receptor subunit genes as a susceptibility class for
          generalized absence epilepsy. Marked PARTIAL because the cited spectrum
          is anchored on childhood absence epilepsy rather than JAE specifically.
  - name: Altered Thalamic Low-Threshold Calcium Bursting
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
    biological_scale: CELLULAR
    description: >-
      Thalamic relay and reticular neurons carry a low-voltage-activated T-type
      calcium current that, when a neuron is hyperpolarized and then released,
      produces a low-threshold calcium spike crowned by a high-frequency burst of
      action potentials. This burst mode is the cellular substrate of the spike
      component of the spike-wave discharge, and it is the target of the
      first-line absence drug ethosuximide.
    cell_types:
      - preferred_term: thalamic relay neuron
        term:
          id: CL:4023068
          label: thalamic excitatory neuron
    biological_processes:
      - preferred_term: T-type calcium current in thalamic neurons
        term:
          id: GO:0090676
          label: calcium ion transmembrane transport via low voltage-gated calcium channel
        modifier: INCREASED
    downstream:
      - target: Hypersynchronous Thalamocortical Oscillation
    evidence:
      - reference: PMID:11896171
        reference_title: >-
          Activity of thalamic reticular neurons during spontaneous genetically
          determined spike and wave discharges.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          The prolonged (up to 15 action potentials), high-frequency bursts
          present during SWDs were tightly synchronized between adjacent neurons,
          correlated with the EEG spike component, and generated by a
          low-threshold Ca(2+) potential
        explanation: >-
          Intracellular recordings during spontaneous spike-wave discharges in the
          GAERS rat tie the EEG spike component directly to low-threshold
          calcium-generated bursts, the cellular event this node asserts.
      - reference: PMID:22344687
        reference_title: >-
          T-type calcium channel blockers that attenuate thalamic burst firing and
          suppress absence seizures.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          we identified the T-type Ca(2+) channel blockers Z941 and Z944 as
          candidate agents and showed in thalamic slices that they attenuated
          burst firing of thalamic reticular nucleus neurons in GAERS
        explanation: >-
          Pharmacological confirmation running the other direction: selectively
          blocking the T-type current attenuates the burst firing and suppresses
          absence seizures, supporting a causal rather than merely correlative
          role.
  - name: Aberrant GABAergic Inhibition in the Thalamic Reticular Nucleus
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
    biological_scale: CELLULAR
    description: >-
      The thalamic reticular nucleus is a GABAergic shell that inhibits thalamic
      relay neurons. The rhythmic hyperpolarization it imposes is what
      de-inactivates T-type calcium channels in relay cells and licenses the next
      burst, making reticular GABAergic output the pacemaker candidate for the
      spike-wave rhythm. Recordings in genetic models show reticular neurons fire
      synchronized bursts locked to the EEG spike while retaining intranuclear
      lateral inhibition.
    cell_types:
      - preferred_term: GABAergic neuron of the thalamic reticular nucleus
        term:
          id: CL:0000617
          label: GABAergic neuron
    biological_processes:
      - preferred_term: gamma-aminobutyric acid signaling pathway
        term:
          id: GO:0007214
          label: gamma-aminobutyric acid signaling pathway
        modifier: ABNORMAL
    downstream:
      - target: Altered Thalamic Low-Threshold Calcium Bursting
      - target: Hypersynchronous Thalamocortical Oscillation
    evidence:
      - reference: PMID:11896171
        reference_title: >-
          Activity of thalamic reticular neurons during spontaneous genetically
          determined spike and wave discharges.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          This novel finding demonstrates that spontaneous genetically determined
          SWDs occur in the presence of intra-NRT lateral inhibition.
        explanation: >-
          Directly characterizes reticular thalamic GABAergic behaviour during
          genetically determined spike-wave discharges, the claim of this node.
  - name: Corticothalamic Drive from Deep-Layer Cortical Neurons
    biological_scale: CELLULAR
    description: >-
      Layer VI pyramidal neurons supply the sole descending cortical input to
      thalamic relay and reticular cells. Selectively removing P/Q-type calcium
      channels from these neurons alone is sufficient to produce a spontaneous,
      ethosuximide-responsive spike-wave absence phenotype, showing that the
      cortical arm of the loop is not merely a passive recipient of a thalamic
      rhythm.
    cell_types:
      - preferred_term: layer VI corticothalamic projection neuron
        term:
          id: CL:4023013
          label: corticothalamic-projecting glutamatergic cortical neuron
    downstream:
      - target: Hypersynchronous Thalamocortical Oscillation
    evidence:
      - reference: PMID:26758833
        reference_title: >-
          Isolated P/Q Calcium Channel Deletion in Layer VI Corticothalamic
          Neurons Generates Absence Epilepsy.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Targeted Cacna1a ablation in layer VI cells resulted in mice that
          display a robust spontaneous spike-wave absence seizure phenotype
          accompanied by behavioral arrest and inhibited by ethosuximide.
        explanation: >-
          Establishes that a lesion confined to the corticothalamic arm is
          sufficient to generate the absence phenotype, supporting a cortical
          contribution to ictogenesis independent of a primary thalamic defect.
  - name: Hypersynchronous Thalamocortical Oscillation
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
    biological_scale: TISSUE
    description: >-
      Recurrent excitation and inhibition around the cortex-thalamus-reticular
      loop entrains large neuronal populations into a pathological synchronized
      rhythm. Network analyses in drug-naive JAE patients show the reorganization
      is not confined to the seizure itself: interictal network efficiency is
      already abnormal between seizures.
    downstream:
      - target: Generalized Spike-Wave Discharges
    evidence:
      - reference: PMID:22344687
        reference_title: >-
          T-type calcium channel blockers that attenuate thalamic burst firing and
          suppress absence seizures.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          They arise from abnormal, hypersynchronous neuronal firing in brain
          thalamocortical circuits.
        explanation: >-
          States the thalamocortical hypersynchrony mechanism that this node
          represents.
      - reference: PMID:38550342
        reference_title: >-
          Exploring brain network oscillations during seizures in drug-naïve
          patients with juvenile absence epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Compared with the resting state of the HC group, the global efficiency,
          local efficiency, and clustering coefficients of the JAE group decreased
          in the inter-ictal state.
        explanation: >-
          Graph-theoretic EEG analysis in untreated JAE patients specifically,
          showing that network topology is abnormal even between seizures, which
          supports a persistent network state rather than a purely paroxysmal one.
      - reference: PMID:37925871
        reference_title: >-
          Dynamic alterations of striatal-related functional networks in juvenile
          absence epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We found altered dFC variability of striatal-cortical/subcortical
          networks in patients with JAE.
        explanation: >-
          Extends the abnormal-network claim beyond the classic thalamocortical
          loop to striatal circuits in JAE patients. Marked PARTIAL because
          resting-state connectivity change is correlational and does not by
          itself establish that the striatum participates in generating the
          discharge.
  - name: Generalized Spike-Wave Discharges
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Seizure Generation and Epileptogenesis"
    biological_scale: ORGANISM
    description: >-
      Bilaterally synchronous generalized spike-wave activity is the
      electrographic signature of the syndrome. The ILAE places the acceptable
      frequency band for generalized spike-wave in the idiopathic generalized
      epilepsies at 2.5 to 5.5 Hz; JAE discharges are typically at the faster end
      of the classic 3 Hz absence rhythm.
    downstream:
      - target: Absence Seizures
        causal_link_type: DIRECT
        description: >-
          The absence seizure is the behavioural expression of the generalized
          spike-wave discharge; the two are time-locked rather than merely
          associated.
        evidence:
          - reference: PMID:22344687
            reference_title: >-
              T-type calcium channel blockers that attenuate thalamic burst firing
              and suppress absence seizures.
            supports: SUPPORT
            evidence_source: OTHER
            snippet: >-
              Absence seizures are a common seizure type in children with genetic
              generalized epilepsy and are characterized by a temporary loss of
              awareness, arrest of physical activity, and accompanying
              spike-and-wave discharges on an electroencephalogram.
            explanation: >-
              States the coupling of the clinical absence to the accompanying
              spike-wave discharge, which is the content of this edge.
      - target: Generalized Tonic-Clonic Seizures
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
        description: >-
          Generalized tonic-clonic seizures arise from the same generalized
          epileptic network, but the transition from spike-wave activity to a
          tonic-clonic seizure is not mechanistically resolved, so the edge is
          recorded as indirect with unknown intermediates.
    evidence:
      - reference: PMID:35503716
        reference_title: >-
          ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:
          Position statement by the ILAE Task Force on Nosology and Definitions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          with 2.5-5.5 Hz generalized spike-wave
        explanation: >-
          Gives the ILAE-sanctioned generalized spike-wave frequency band for the
          idiopathic generalized epilepsies, of which JAE is one.
  - name: Absence Seizures
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
    biological_scale: ORGANISM
    description: >-
      Behavioral arrest with impairment of awareness, time-locked to the
      generalized spike-wave discharge. In JAE these are less frequent than the
      pyknoleptic, many-times-daily absences of childhood absence epilepsy.
    evidence:
      - reference: PMID:22344687
        reference_title: >-
          T-type calcium channel blockers that attenuate thalamic burst firing and
          suppress absence seizures.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          characterized by a temporary loss of awareness, arrest of physical
          activity, and accompanying spike-and-wave discharges on an
          electroencephalogram
        explanation: >-
          Defines the clinical content of the absence seizure that this terminal
          node represents.
  - name: Generalized Tonic-Clonic Seizures
    biological_scale: ORGANISM
    description: >-
      Most patients with JAE also have generalized tonic-clonic seizures, which
      distinguishes the syndrome clinically from childhood absence epilepsy and
      is a principal driver of the need for long-term treatment.
    evidence:
      - reference: PMID:32644481
        reference_title: Juvenile Absence Epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          is characterized by absence seizures and generalized tonic-clonic
          seizures
        explanation: >-
          Establishes generalized tonic-clonic seizures as a defining component of
          the JAE syndrome, which is what this terminal node asserts.
phenotypes:
  - name: Typical Absence Seizures
    category: Neurologic
    description: >-
      Abrupt-onset, abrupt-offset impairment of awareness, the defining seizure
      type of JAE. Absences are less frequent and often somewhat longer, with
      less complete loss of awareness, than the pyknoleptic absences of childhood
      absence epilepsy.
    phenotype_term:
      preferred_term: Typical absence seizure
      term:
        id: HP:0011147
        label: Typical absence seizure
      onset:
        onset_category: JUVENILE
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:32644481
        reference_title: Juvenile Absence Epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Juvenile absence epilepsy is an idiopathic generalized epilepsy syndrome
          that is recognized by the ILAE (International League Against Epilepsy)
          that typically starts in adolescence around puberty and is characterized
          by absence seizures and generalized tonic-clonic seizures.
        explanation: >-
          Names absence seizures as a defining feature of the syndrome. Frequency
          is set VERY_FREQUENT because absence seizures are definitional for JAE,
          so essentially all diagnosed patients have them.
      - reference: PMID:38550342
        reference_title: >-
          Exploring brain network oscillations during seizures in drug-naïve
          patients with juvenile absence epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Thirty-six juvenile absence epilepsy (JAE) patients with a current high
          frequency of seizures (more than five seizures during a 2 h EEG
          examination) were included.
        explanation: >-
          Primary-cohort documentation of recorded absence seizures in
          syndrome-diagnosed JAE patients, so the phenotype does not rest on a
          tertiary clinical reference alone.
  - name: Generalized Tonic-Clonic Seizures
    category: Neurologic
    description: >-
      Bilateral tonic-clonic seizures of generalized onset occur in the great
      majority of patients with JAE and are the main reason long-term antiseizure
      medication is required. Cumulative tonic-clonic seizure burden predicts a
      worse chance of seizure freedom.
    phenotype_term:
      preferred_term: Bilateral tonic-clonic seizure with generalized onset
      term:
        id: HP:0025190
        label: Bilateral tonic-clonic seizure with generalized onset
    evidence:
      - reference: PMID:32644481
        reference_title: Juvenile Absence Epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          typically starts in adolescence around puberty and is characterized by
          absence seizures and generalized tonic-clonic seizures
        explanation: >-
          Names generalized tonic-clonic seizures as a characteristic feature of
          the syndrome alongside absences.
      - reference: PMID:40945312
        reference_title: >-
          Long-term seizure outcomes and the likelihood of antiseizure medication
          withdrawal in patients with juvenile absence epilepsy: A 10-year
          follow-up study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          the total number of generalized tonic-clonic seizures experienced,
          presence of absence seizures on follow-up EEG and the persistence of
          hyperventilation positivity on EEG were associated with an unfavorable
          outcome regarding seizure freedom
        explanation: >-
          A 10-year JAE follow-up cohort showing tonic-clonic seizure burden is
          prognostically important, supporting the clinical weight given to this
          phenotype.
  - name: Myoclonic Jerks
    category: Neurologic
    description: >-
      A minority of patients with JAE have myoclonic jerks in addition to
      absences and tonic-clonic seizures. Prominent myoclonus should prompt
      reconsideration of juvenile myoclonic epilepsy.
    phenotype_term:
      preferred_term: Myoclonic seizure
      term:
        id: HP:0032794
        label: Myoclonic seizure
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:32644481
        reference_title: Juvenile Absence Epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          In some patients, there may be additional myoclonic jerks as well.
        explanation: >-
          States that myoclonic jerks occur in a subset of JAE patients. The
          qualitative phrase "in some patients" maps to OCCASIONAL under the
          project frequency mapping guidance.
  - name: Absence Status Epilepticus
    category: Neurologic
    description: >-
      Prolonged confusional states with subcontinuous generalized spike-wave
      activity on EEG. This is a clinically important complication of JAE because
      it presents as altered mental status rather than as recognizable seizures
      and is readily misattributed to a psychiatric or toxic-metabolic cause,
      delaying EEG and treatment.
    phenotype_term:
      preferred_term: Typical absence status epilepticus
      term:
        id: HP:0032863
        label: Typical absence status epilepticus
    evidence:
      - reference: PMID:30530409
        reference_title: >-
          Juvenile absence epilepsy relapsing as recurrent absence status,
          mimicking transient global amnesia, in an elderly patient.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          AS is common in juvenile absence epilepsy
        explanation: >-
          States directly that absence status epilepticus is common in JAE. No
          frequency band is asserted here because this is a single case report
          making a qualitative claim rather than a cohort measurement.
      - reference: PMID:30530409
        reference_title: >-
          Juvenile absence epilepsy relapsing as recurrent absence status,
          mimicking transient global amnesia, in an elderly patient.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          An EEG disclosed, on both occasions, subcontinuous generalized
          spike-and-wave discharges, consistent with absence status epilepticus
        explanation: >-
          Documents the electrographic substrate of absence status, tying the
          phenotype to the same generalized spike-wave mechanism modelled in the
          pathophysiology section.
  - name: Impaired School Performance
    category: Neurologic
    description: >-
      Population-registry data show a measurable educational cost of JAE that is
      not shared equally by the other idiopathic generalized epilepsies. In a
      Danish national cohort, JAE carried roughly double the hazard of requiring
      special-needs education relative to age-matched population controls, an
      effect not seen in juvenile myoclonic epilepsy.
    phenotype_term:
      preferred_term: Specific learning disability
      term:
        id: HP:0001328
        label: Specific learning disability
    evidence:
      - reference: PMID:35595971
        reference_title: >-
          School performance and psychiatric comorbidity in juvenile absence
          epilepsy and juvenile myoclonic epilepsy: a Danish population-based
          cohort study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          JAE had two times increased hazard for special needs education compared
          with age-matched population controls
        explanation: >-
          Quantifies the educational impact in a JAE-specific national registry
          cohort with population controls, and the same sentence records that the
          effect was absent in juvenile myoclonic epilepsy, which supports treating
          this as syndrome-specific rather than a generic epilepsy effect.
  - name: Generalized Spike-Wave on EEG
    category: Neurologic
    description: >-
      Interictal and ictal EEG shows bilaterally synchronous generalized
      spike-wave complexes on a normal background, typically activated by
      hyperventilation.
    phenotype_term:
      preferred_term: EEG with spike-wave complexes
      term:
        id: HP:0010850
        label: EEG with spike-wave complexes
    evidence:
      - reference: PMID:32644481
        reference_title: Juvenile Absence Epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          with an electroencephalographic pattern of generalized epileptiform
          spike and wave or polyspike and wave discharge, at times with a shifting
          predominance on a normal background
        explanation: >-
          Describes the generalized spike-wave EEG pattern on a normal background
          that characterizes the idiopathic generalized epilepsies including JAE.
  - name: Attention and Cognitive Impairment
    category: Neurologic
    description: >-
      Absence epilepsies carry a substantial neuropsychiatric comorbidity burden.
      Attentional deficits can predate the epilepsy diagnosis, may persist despite
      pharmacological seizure control, and are worsened by valproate monotherapy.
      In JAE specifically, imaging shows structural and functional correlates of a
      cognitive phenotype.
    phenotype_term:
      preferred_term: Attention deficit hyperactivity disorder
      term:
        id: HP:0007018
        label: Attention deficit hyperactivity disorder
    evidence:
      - reference: PMID:32437558
        reference_title: >-
          Clinical and experimental insight into pathophysiology, comorbidity and
          therapy of absence seizures.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          attention deficits can be detected before the epilepsy diagnosis, may
          persist even when seizures are pharmacologically controlled and are
          aggravated by valproic acid monotherapy
        explanation: >-
          Documents the attentional comorbidity of absence epilepsy and its
          aggravation by valproate. Marked PARTIAL because the review addresses
          absence seizures broadly rather than JAE alone.
      - reference: PMID:41531116
        reference_title: >-
          Syndrome-specific and familial imaging traits in juvenile absence
          epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Gray matter volume was reduced in sensorimotor regions and in the left
          inferior and middle frontal gyri in patients.
        explanation: >-
          Provides JAE-specific structural imaging correlates of the cognitive
          profile, anchoring the comorbidity claim in this syndrome rather than in
          absence epilepsy generally.
genetic:
  - name: GABRG2
    gene_term:
      preferred_term: GABRG2
      term:
        id: hgnc:4087
        label: GABRG2
    relationship_type: SUSCEPTIBILITY
    variant_origin: GERMLINE
    notes: >-
      GABRG2 encodes the GABA-A receptor gamma-2 subunit, required for receptor
      trafficking and synaptic clustering. Variants are associated with a spectrum
      of generalized epilepsies that includes generalized absence epilepsy. Listed
      here as a susceptibility contributor to the inhibitory arm of the
      thalamocortical loop, not as a monogenic cause of JAE.
    evidence:
      - reference: PMID:27367160
        reference_title: >-
          Molecular Pathogenic Basis for GABRG2 Mutations Associated With a
          Spectrum of Epilepsy Syndromes, From Generalized Absence Epilepsy to
          Dravet Syndrome.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The γ-aminobutyric acid (GABAA) receptor γ2 subunit gene, GABRG2, is
          abundantly expressed in the mammalian brain
        explanation: >-
          Establishes GABRG2 as an epilepsy gene encoding a subunit of the
          principal inhibitory receptor of the brain. PARTIAL because the reported
          syndrome spectrum is anchored on childhood absence epilepsy rather than
          JAE.
  - name: CACNA1H
    gene_term:
      preferred_term: CACNA1H
      term:
        id: hgnc:1395
        label: CACNA1H
    relationship_type: MODIFIER
    variant_origin: GERMLINE
    notes: >-
      CACNA1H encodes the Cav3.2 T-type calcium channel, the channel that carries
      the thalamic low-threshold current central to this entry's mechanism. It is
      retained here as a mechanistically motivated but formally DISPUTED
      association, not as a diagnostic gene. ClinGen has reclassified the
      gene-disease relationship as disputed, and the disputing analysis
      recommended removing CACNA1H from commercial epilepsy panels. See the
      cacna1h_disputed_gene_disease_validity discussion.
    evidence:
      - reference: PMID:32227660
        reference_title: CACNA1H variants are not a cause of monogenic epilepsy.
        supports: REFUTE
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          we conclude that there is limited evidence that CACNA1H is a monogenic
          cause of epilepsy in humans and that this gene should be removed from
          commercial genetic testing panels
        explanation: >-
          Explicitly refutes CACNA1H as a monogenic epilepsy cause. Recorded as
          REFUTE so the entry carries the disconfirming evidence rather than an
          uncontested legacy association.
      - reference: PMID:32227660
        reference_title: CACNA1H variants are not a cause of monogenic epilepsy.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          in support of Cav3.2 contributing to seizure susceptibility as a
          modifier
        explanation: >-
          The positive evidence for the MODIFIER typing used here. From the same
          analysis that refutes the monogenic claim, this preserves the surviving
          modifier role observed in the GAERS rat. PARTIAL because the modifier
          effect is demonstrated in a rodent model rather than in human JAE.
prevalence:
  - population: Idiopathic generalized epilepsy clinic populations
    measure_type: UNKNOWN
    prevalence_class: RARE
    notes: >-
      JAE is one of the four ILAE idiopathic generalized epilepsy syndromes; the
      IGEs together account for roughly 20 to 40 percent of all epilepsies, with
      JAE the least common of the absence syndromes. Syndrome-specific
      population-based incidence estimates are not well established, so no
      normalized rate is asserted here.
    evidence:
      - reference: PMID:32644481
        reference_title: Juvenile Absence Epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Idiopathic generalized epilepsy is a group of epilepsies accounting for
          about 20 to 40% of all epilepsies.
        explanation: >-
          Gives the share of epilepsy attributable to the IGE group as a whole.
          Marked PARTIAL because it bounds rather than measures JAE specifically,
          which is why no rate_per_100000 is asserted.
progression:
  - phase: Persistence into adulthood with attempted medication withdrawal
    age_range: Adolescence to adulthood
    notes: >-
      In contrast to childhood absence epilepsy, JAE usually persists. In a
      10-year follow-up cohort, about two thirds of patients reached at least two
      years of seizure freedom on medication, and roughly half attempted
      medication withdrawal, but only a small number ultimately discontinued
      treatment entirely. EEG abnormalities improved over follow-up in most
      patients.
    evidence:
      - reference: PMID:40945312
        reference_title: >-
          Long-term seizure outcomes and the likelihood of antiseizure medication
          withdrawal in patients with juvenile absence epilepsy: A 10-year
          follow-up study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Among these patients, 38 (65.5 %) achieved seizure freedom for at least
          2 years.
        explanation: >-
          Quantifies the seizure-freedom rate in a JAE-specific long-term cohort.
      - reference: PMID:40945312
        reference_title: >-
          Long-term seizure outcomes and the likelihood of antiseizure medication
          withdrawal in patients with juvenile absence epilepsy: A 10-year
          follow-up study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          After a median EEG follow-up period of 6 years, abnormal EEG improved in
          34 of the 58 patients
        explanation: >-
          Documents EEG improvement over long-term follow-up, supporting the
          electrographic component of the progression claim.
treatments:
  - name: Valproate
    description: >-
      Broad-spectrum antiseizure medication effective against both the absence
      and the generalized tonic-clonic seizures of JAE, and an independent
      predictor of seizure freedom in long-term follow-up. Its use is constrained
      by teratogenicity and by aggravation of attentional deficits, which is why
      it is generally avoided as first-line therapy in girls and women of
      childbearing potential.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: valproic acid
          term:
            id: CHEBI:39867
            label: valproic acid
    target_mechanisms:
      - target: Hypersynchronous Thalamocortical Oscillation
        treatment_effect: INHIBITS
    evidence:
      - reference: PMID:40945312
        reference_title: >-
          Long-term seizure outcomes and the likelihood of antiseizure medication
          withdrawal in patients with juvenile absence epilepsy: A 10-year
          follow-up study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Treatment with valproate was identified as an independent predictor of a
          favorable outcome in terms of seizure freedom.
        explanation: >-
          JAE-specific cohort evidence that valproate treatment predicts seizure
          freedom.
      - reference: PMID:32437558
        reference_title: >-
          Clinical and experimental insight into pathophysiology, comorbidity and
          therapy of absence seizures.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          are aggravated by valproic acid monotherapy
        explanation: >-
          Records the cognitive cost of valproate monotherapy, which is the
          counterweight to its efficacy. PARTIAL because the observation is made
          for absence epilepsy broadly.
  - name: Ethosuximide
    description: >-
      A T-type calcium channel blocker that acts directly on the thalamic
      low-threshold burst mechanism modelled in this entry. It is effective
      against absence seizures but does not protect against generalized
      tonic-clonic seizures, which limits its usefulness as monotherapy in JAE
      given the high tonic-clonic burden of the syndrome.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: ethosuximide
          term:
            id: CHEBI:4887
            label: ethosuximide
    target_mechanisms:
      - target: Altered Thalamic Low-Threshold Calcium Bursting
        treatment_effect: INHIBITS
    evidence:
      - reference: PMID:26758833
        reference_title: >-
          Isolated P/Q Calcium Channel Deletion in Layer VI Corticothalamic
          Neurons Generates Absence Epilepsy.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          a robust spontaneous spike-wave absence seizure phenotype accompanied by
          behavioral arrest and inhibited by ethosuximide
        explanation: >-
          Demonstrates ethosuximide suppression of the spike-wave absence
          phenotype in a corticothalamic genetic model, linking the drug to the
          mechanism node it targets.
  - name: Lamotrigine
    description: >-
      Broad-spectrum antiseizure medication and a preferred first-line
      alternative to valproate for women of childbearing age with JAE. A
      multicentre Bayesian comparative-effectiveness reanalysis found lamotrigine
      superior to levetiracetam on treatment failure and drug retention in this
      population.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: lamotrigine
          term:
            id: CHEBI:6367
            label: lamotrigine
    evidence:
      - reference: PMID:39126356
        reference_title: >-
          Lamotrigine vs levetiracetam in female patients of childbearing age with
          juvenile absence epilepsy: A Bayesian reanalysis.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Bayesian reanalysis supports LTG as first-line monotherapy for JAE in
          women of childbearing age, emphasizing the importance of individualized
          treatment strategies in women with IGE.
        explanation: >-
          Directly supports lamotrigine as first-line monotherapy in the JAE
          subgroup where valproate is contraindicated.
  - name: Levetiracetam
    description: >-
      Broad-spectrum antiseizure medication used in JAE, particularly where
      valproate is unsuitable. In the JAE-specific Bayesian comparison it
      underperformed lamotrigine on treatment failure and retention, although the
      two did not differ detectably on outright seizure freedom.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: levetiracetam
          term:
            id: CHEBI:6437
            label: levetiracetam
    evidence:
      - reference: PMID:39126356
        reference_title: >-
          Lamotrigine vs levetiracetam in female patients of childbearing age with
          juvenile absence epilepsy: A Bayesian reanalysis.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          whereas the two ASMs did not show evident differences in terms of
          seizure freedom
        explanation: >-
          Supports levetiracetam as a usable option while recording that it was
          inferior on the primary effectiveness endpoints. PARTIAL because the
          evidence qualifies rather than endorses the treatment.
  - name: Selective Sodium Channel Blockers (Seizure-Aggravating)
    description: >-
      Selective sodium channel blockers, principally carbamazepine and its
      relatives oxcarbazepine and phenytoin, carry a recognized risk of seizure
      worsening in the genetic generalized epilepsies and are generally avoided
      in JAE. This is modelled as a treatment entry with an aggravating rather
      than therapeutic target_mechanisms link so that the contraindication sits
      on the pathograph instead of floating free as a warning.

      Scope of the evidence. The cited cohort covers selective sodium channel
      blockers only, and its observed aggravation was significantly associated
      with juvenile myoclonic epilepsy rather than with JAE, so the edge is
      recorded against the shared generalized hypersynchrony node rather than
      against a JAE-specific mechanism.

      Not evidenced here. The GABA-elevating agents vigabatrin and tiagabine, and
      the gabapentinoids, are also classically listed as absence-aggravating, and
      the usual mechanistic account is that raising thalamic GABA tone increases
      GABA-B-mediated hyperpolarization of relay neurons, de-inactivating T-type
      calcium channels and licensing more burst firing. That account is
      biologically continuous with the mechanism this entry models, but no
      citable source for it was located in this curation pass, so it is stated
      here as background rather than curated as an evidenced mechanism edge.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: carbamazepine
          term:
            id: CHEBI:3387
            label: carbamazepine
    target_mechanisms:
      - target: Hypersynchronous Thalamocortical Oscillation
        treatment_effect: ACTIVATES
        description: >-
          Recorded as ACTIVATES to make the direction of harm explicit: these
          agents can worsen rather than suppress generalized seizures. The target
          is the shared hypersynchrony node rather than a specific channel or
          receptor node, because the cited evidence reports clinical seizure
          worsening in genetic generalized epilepsy without identifying the
          molecular step responsible.
    evidence:
      - reference: PMID:34314016
        reference_title: >-
          Reconsidering the role of selective sodium channel blockers in genetic
          generalized epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Selective sodium channel blockers (SSCBs) have a limited use in genetic
          generalized epilepsy (GGE), due to their well-known risk of seizure
          worsening.
        explanation: >-
          States the seizure-worsening risk that motivates treating these agents
          as contraindicated in the genetic generalized epilepsies, of which JAE
          is one.
      - reference: PMID:34314016
        reference_title: >-
          Reconsidering the role of selective sodium channel blockers in genetic
          generalized epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Seizure worsening was reported in 5/56 patients
        explanation: >-
          Quantifies observed aggravation in a genetic generalized epilepsy
          cohort. Marked PARTIAL because the cohort is mixed-syndrome and the
          aggravation was significantly associated with juvenile myoclonic
          epilepsy rather than with JAE specifically, so the figure bounds rather
          than measures the JAE risk.
diagnosis:
  - name: Hyperventilation-activated EEG
    description: >-
      Routine EEG with a standardized period of hyperventilation is the
      highest-yield single test. Hyperventilation reliably provokes generalized
      spike-wave activity and often a clinical absence in untreated patients,
      which converts an intermittent history into a recorded event. Persistence
      of hyperventilation positivity on follow-up EEG carries prognostic weight,
      being associated with a lower chance of seizure freedom.
    diagnosis_term:
      preferred_term: Electroencephalography
      term:
        id: NCIT:C38054
        label: Electroencephalography
    results: >-
      Bilaterally synchronous generalized spike-wave discharges on a normal
      background, frequently with a clinical absence during hyperventilation.
    evidence:
      - reference: PMID:40945312
        reference_title: >-
          Long-term seizure outcomes and the likelihood of antiseizure medication
          withdrawal in patients with juvenile absence epilepsy: A 10-year
          follow-up study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          the persistence of hyperventilation positivity on EEG were associated
          with an unfavorable outcome regarding seizure freedom
        explanation: >-
          Establishes hyperventilation EEG activation as a used and
          prognostically informative element of JAE assessment.
  - name: Paired CSF and plasma glucose for GLUT1 deficiency
    description: >-
      Because GLUT1 deficiency can present as absence epilepsy and is treatable
      with the ketogenic diet, a low CSF-to-plasma glucose ratio on paired
      fasting samples, followed by SLC2A1 testing, is the mechanism-directed
      screening step. The yield is highest in early-onset absence epilepsy but
      the familial form has widely variable onset, so it remains worth
      considering in atypical or treatment-refractory presentations.
    diagnosis_term:
      preferred_term: paired fasting CSF and plasma glucose measurement
    results: >-
      A reduced CSF-to-plasma glucose ratio supports GLUT1 deficiency and prompts
      SLC2A1 sequencing and deletion analysis.
    evidence:
      - reference: PMID:23106342
        reference_title: >-
          Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1
          deficiency.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Given the major treatment and genetic counseling implications, this
          study confirms that SLC2A1 mutational
        explanation: >-
          States the treatment and counselling rationale that justifies screening
          for GLUT1 deficiency in absence epilepsy.
clinical_trials:
  - name: NCT04666610
    phase: PHASE_II
    description: >-
      N01269, a randomized, double-blind, placebo-controlled adaptive phase 2/3
      trial of brivaracetam monotherapy in patients aged 2 to 25 years with
      childhood or juvenile absence epilepsy. It is one of the few
      interventional trials that enrolls JAE as a named syndrome rather than
      folding it into undifferentiated generalized epilepsy.
    target_phenotypes:
      - preferred_term: Typical absence seizure
        term:
          id: HP:0011147
          label: Typical absence seizure
    evidence:
      - reference: PMID:35844134
        reference_title: >-
          Efficacy and tolerability of brivaracetam monotherapy in childhood and
          juvenile absence epilepsy: An innovative adaptive trial design.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We report the innovative adaptive design of an ongoing phase 2/3 trial
          to evaluate efficacy, safety, and tolerability of brivaracetam (BRV)
          monotherapy in patients 2-25 years of age with CAE or JAE.
        explanation: >-
          Describes the trial and confirms that JAE is an enrolled population,
          which is why it is recorded here rather than only under childhood
          absence epilepsy.
differential_diagnoses:
  - name: Childhood Absence Epilepsy
    disease_term:
      preferred_term: childhood absence epilepsy
      term:
        id: MONDO:0010826
        label: childhood absence epilepsy
    description: >-
      The nearest neighbour of JAE and the hardest to separate, because the two
      share the thalamocortical mechanism, the EEG signature, and much of their
      candidate genetics. The age-of-onset boundary between them is a
      curation-relevant open question, recorded in the discussions block.
    distinguishing_features:
      - Earlier onset, typically in mid-childhood rather than around puberty.
      - Pyknoleptic absences occurring many times daily rather than sporadically.
      - Much lower burden of generalized tonic-clonic seizures.
      - High rate of spontaneous remission, whereas JAE usually persists.
    evidence:
      - reference: PMID:35503716
        reference_title: >-
          ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:
          Position statement by the ILAE Task Force on Nosology and Definitions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          The goal of this paper is to delineate the four syndromes comprising the
          IGEs, namely childhood absence epilepsy, juvenile absence epilepsy,
          juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic
          seizures alone.
        explanation: >-
          Establishes that the ILAE treats childhood absence epilepsy and juvenile
          absence epilepsy as separate syndromes requiring differentiation, which
          is what makes this a differential rather than a synonym.
  - name: Juvenile Myoclonic Epilepsy
    disease_term:
      preferred_term: juvenile myoclonic epilepsy
      term:
        id: MONDO:0009696
        label: juvenile myoclonic epilepsy
    description: >-
      Overlaps with JAE in age of onset and in the occurrence of absences,
      myoclonus, and generalized tonic-clonic seizures, but is defined by
      prominent myoclonic jerks, characteristically on awakening. The two
      syndromes also diverge on measured outcomes rather than only on semiology.
    distinguishing_features:
      - Prominent myoclonic jerks, typically on awakening, are definitional.
      - Absence seizures are not required for the diagnosis.
      - Functional and structural imaging reorganization patterns differ from JAE.
      - The doubled hazard for special-needs education seen in JAE is not seen here.
    evidence:
      - reference: PMID:35595971
        reference_title: >-
          School performance and psychiatric comorbidity in juvenile absence
          epilepsy and juvenile myoclonic epilepsy: a Danish population-based
          cohort study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          JAE had two times increased hazard for special needs education compared
          with age-matched population controls (hazard ratio 2.2, 95% CI =
          1.1‒4.6, p = 0.03); this was not seen in JME.
        explanation: >-
          Provides a measured outcome difference between the two syndromes rather
          than a purely semiological distinction, supporting their separation.
  - name: Epilepsy with Generalized Tonic-Clonic Seizures Alone
    description: >-
      The fourth ILAE idiopathic generalized epilepsy syndrome. Shares the
      generalized spike-wave EEG and the adolescent onset but lacks absence
      seizures as a defining feature. No MONDO binding is asserted here because
      no MONDO term for this ILAE 2022 syndrome was resolvable at curation time.
    distinguishing_features:
      - Absence seizures are absent, whereas they are definitional for JAE.
      - Generalized tonic-clonic seizures are the sole seizure type.
    evidence:
      - reference: PMID:35503716
        reference_title: >-
          ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:
          Position statement by the ILAE Task Force on Nosology and Definitions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic
          seizures alone
        explanation: >-
          Names this syndrome as one of the four ILAE idiopathic generalized
          epilepsies that must be distinguished from JAE.
  - name: GLUT1 Deficiency
    disease_term:
      preferred_term: encephalopathy due to GLUT1 deficiency
      term:
        id: MONDO:0011724
        label: encephalopathy due to GLUT1 deficiency
    description: >-
      SLC2A1 loss of function impairs glucose transport across the blood-brain
      barrier, and the resulting cerebral energy deficit can present as absence
      epilepsy that phenocopies an idiopathic generalized syndrome. It is
      modelled here as a differential rather than as a cause of JAE because the
      mechanism is metabolic rather than a thalamocortical channel or receptor
      defect, and because the published yield comes from early-onset absence
      cohorts, before age four, rather than from JAE-diagnosed patients. The
      familial form nevertheless has widely variable onset, so it stays on the
      differential list for atypical or refractory presentations. This is the one
      differential that changes management, since the ketogenic diet supplies
      ketone bodies as an alternative fuel that bypasses the missing transporter.
      The diet is deliberately not listed under this entry's treatments, because
      it treats this differential rather than JAE itself and no JAE-specific
      evidence for it was found in this curation pass.
    distinguishing_features:
      - Reduced CSF-to-plasma glucose ratio on paired fasting samples.
      - Pathogenic SLC2A1 variant, often autosomal dominant and familial.
      - Paroxysmal exertional dyskinesia in some affected family members.
      - Onset typically before four years of age in the screened cohorts.
      - Responsive to the ketogenic diet, unlike polygenic JAE.
    evidence:
      - reference: PMID:23106342
        reference_title: >-
          Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1
          deficiency.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Over both studies, 11 (12%) of 89 probands with EOAE have GLUT1
          deficiency.
        explanation: >-
          Quantifies the yield of SLC2A1 testing in early-onset absence epilepsy,
          establishing GLUT1 deficiency as a non-trivial share of absence
          presentations and therefore a differential worth screening for.
      - reference: PMID:20574033
        reference_title: >-
          Absence epilepsies with widely variable onset are a key feature of
          familial GLUT1 deficiency.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Familial glucose transporter type 1 (GLUT1) deficiency due to autosomal
          dominant inheritance of SLC2A1 mutations is associated with paroxysmal
          exertional dyskinesia; epilepsy and intellectual disability occur in
          some family members.
        explanation: >-
          Establishes the autosomal dominant familial form and its extra-epileptic
          features, which are the clinical handles that separate it from polygenic
          JAE.
discussions:
  - discussion_id: jae_thalamic_versus_cortical_ictogenesis
    kind: CONTROVERSY
    status: UNDER_DISCUSSION
    prompt: >-
      Is the generalized spike-wave discharge of juvenile absence epilepsy
      initiated by a thalamic pacemaker, or does it originate in cortex and merely
      recruit the thalamus, and does the answer change what should be considered
      the primary drug target?
    attaches_to:
      - pathophysiology#Aberrant GABAergic Inhibition in the Thalamic Reticular Nucleus
      - pathophysiology#Corticothalamic Drive from Deep-Layer Cortical Neurons
      - pathophysiology#Hypersynchronous Thalamocortical Oscillation
    rationale: >-
      The classical account, and the one that motivates ethosuximide, places the
      pacemaker in thalamus: reticular GABAergic neurons rhythmically
      hyperpolarize relay cells, de-inactivating T-type calcium channels and
      producing the burst that becomes the EEG spike. Intracellular recordings in
      the GAERS rat support that reticular neurons burst in tight synchrony with
      the EEG spike. But a competing body of work locates initiation in cortex.
      Focal tetrodotoxin inactivation of facial somatosensory cortex in GAERS
      abolishes paroxysmal activity both locally and in the thalamic neurons
      connected to it, whereas inactivating a remote motor cortical region or the
      related thalamic nuclei does not; and deleting P/Q calcium channels from
      layer VI corticothalamic neurons alone is sufficient to produce spontaneous
      spike-wave absence seizures. A 2020 synthesis states outright that cortical
      rather than exclusively thalamic mechanisms drive ictogenesis and set the
      spike-wave frequency. This entry therefore models both arms as contributing
      nodes rather than asserting a single origin. The stake is practical: if
      ictogenesis is cortical, thalamic T-type blockade is treating a downstream
      amplifier rather than the initiator, which would help explain why
      ethosuximide controls absences but not the tonic-clonic seizures that
      dominate JAE morbidity. It is also worth noting that the decisive
      experiments are rodent genetic models of childhood-type absence, so their
      transfer to the peri-pubertal human syndrome is itself unestablished.
    proposed_experiments:
      - experiment_id: exp_jae_meg_eeg_onset_localization
        name: High-density MEG-EEG source localization of spike-wave onset in JAE
        description: >-
          Simultaneous high-density EEG and magnetoencephalography in drug-naive
          JAE patients, with source reconstruction of the first tens of
          milliseconds of each generalized spike-wave discharge, testing whether a
          reproducible cortical onset zone precedes thalamic recruitment as it
          does in rodent models.
        decision_criterion: >-
          A consistent cortical lead over thalamic activity at discharge onset
          would support cortical ictogenesis in the human syndrome; simultaneous
          or thalamus-leading onset would support the thalamic pacemaker account.
      - experiment_id: exp_jae_targeted_ttype_blocker_trial
        name: Selective T-type calcium channel blocker trial in JAE
        description: >-
          Clinical trial of a selective T-type calcium channel antagonist in JAE,
          reporting absence and generalized tonic-clonic outcomes separately
          rather than pooled.
        decision_criterion: >-
          Suppression of absences without effect on tonic-clonic seizures would
          indicate the thalamic burst mechanism is specific to the absence
          phenotype and not the whole syndrome; suppression of both would argue
          the thalamic node is upstream of the shared generalized mechanism.
    evidence:
      - reference: PMID:32437558
        reference_title: >-
          Clinical and experimental insight into pathophysiology, comorbidity and
          therapy of absence seizures.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          in contrast to the predominant opinion, cortical mechanisms, rather than
          an exclusively thalamic rhythmogenesis, are key in driving seizure
          ictogenesis and determining spike-wave frequency
        explanation: >-
          States the cortical position of the controversy explicitly, and
          acknowledges that it contradicts the prevailing view.
      - reference: PMID:19276326
        reference_title: >-
          Inactivation of the somatosensory cortex prevents paroxysmal
          oscillations in cortical and related thalamic neurons in a genetic model
          of absence epilepsy.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          This study demonstrates that SWDs in GAERS have a focal origin within
          the facial somatosensory cortex, which is sufficient and necessary to
          generate ictal activities.
        explanation: >-
          The experimental basis for the cortical focus position, using targeted
          inactivation to establish necessity and sufficiency in a genetic rat
          model.
      - reference: PMID:11896171
        reference_title: >-
          Activity of thalamic reticular neurons during spontaneous genetically
          determined spike and wave discharges.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          A SWD started with a large hyperpolarization, which was independent of
          the preceding firing
        explanation: >-
          Evidence for the thalamic side of the controversy: reticular thalamic
          neurons show a stereotyped hyperpolarization at discharge onset that is
          not explained by their own prior firing.
      - reference: PMID:11850474
        reference_title: >-
          Cortical focus drives widespread corticothalamic networks during
          spontaneous absence seizures in rats.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          These findings argue against the existence of one common subcortical
          pacemaker for the generation of generalized spike-wave discharges
          characteristic for absence seizures in the rat.
        explanation: >-
          The independent rat model (WAG/Rij) that first argued against a single
          subcortical pacemaker, using time-delay analysis rather than
          inactivation, so the cortical position rests on two different
          experimental designs in two different genetic models.
  - discussion_id: jae_cortical_focus_human_translation
    kind: HUMAN_MODEL_MISMATCH
    status: OPEN
    prompt: >-
      The cortical initiation focus for spike-wave discharges is established in
      rodent genetic models and localizes to somatosensory cortex, a region with
      no obvious counterpart role in human juvenile absence epilepsy. Does a
      discrete, anatomically stereotyped cortical focus exist in human JAE at all?
    attaches_to:
      - pathophysiology#Corticothalamic Drive from Deep-Layer Cortical Neurons
      - pathophysiology#Hypersynchronous Thalamocortical Oscillation
    rationale: >-
      This is a translational-validity problem rather than an absence of evidence,
      which is why it is recorded as a human-model mismatch and not as a plain
      knowledge gap. Both pillars of the cortical focus argument are rodent: the
      WAG/Rij time-delay analysis localizing a focus to the peri-oral
      somatosensory cortex, and the GAERS tetrodotoxin inactivation showing that
      focus is necessary and sufficient. The WAG/Rij authors themselves hedged the
      extrapolation, writing only that analogous mechanisms may underlie human
      absence epilepsy. The mismatch has three parts. First, the rodent focus sits
      in the peri-oral somatosensory cortex, whereas human absence-epilepsy
      imaging implicates frontal and default-mode network structures rather than a
      single stereotyped sensory locus; JAE-specific structural imaging finds
      reduced grey matter in sensorimotor and frontal regions without identifying
      a discrete ictal generator. Second, the rodent models are models of
      childhood-onset absence, not of a peri-pubertal syndrome; nothing in them
      speaks to the JAE-specific features of later onset and high tonic-clonic
      burden. Third, if the human equivalent is a distributed network state rather
      than a focus, then focal interventions suggested by the rodent work,
      including targeted neuromodulation, do not have an obvious human target.
    proposed_experiments:
      - experiment_id: exp_human_jae_focus_search_intracranial
        name: Search for a reproducible cortical onset zone in human generalized spike-wave
        description: >-
          Analysis of intracranial or high-density scalp recordings from patients
          with idiopathic generalized epilepsy who have undergone invasive
          monitoring or dense EEG, applying the same nonlinear time-delay
          association methods used in the WAG/Rij rat to test whether a consistent
          cortical site leads the rest of the network at discharge onset.
        decision_criterion: >-
          A reproducible leading cortical site across patients would establish that
          the rodent focus concept transfers; heterogeneous or absent leading sites
          would indicate the human syndrome is a distributed network disorder and
          that the focus model should not be carried over.
      - experiment_id: exp_jae_specific_rodent_model_peripubertal
        name: Peri-pubertal-onset absence model with tonic-clonic seizures
        description: >-
          Development or characterization of a rodent or other animal model in
          which absence seizures emerge around puberty and are accompanied by
          generalized tonic-clonic seizures, matching the JAE phenotype rather
          than the childhood absence phenotype the existing models reproduce.
        decision_criterion: >-
          A model that reproduces peri-pubertal onset and tonic-clonic burden would
          allow the cortical-focus question to be asked for JAE specifically rather
          than inferred from childhood absence models.
    evidence:
      - reference: PMID:11850474
        reference_title: >-
          Cortical focus drives widespread corticothalamic networks during
          spontaneous absence seizures in rats.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Analogous mechanisms may underlie the pathophysiology of human absence
          epilepsy.
        explanation: >-
          The authors' own explicitly hedged extrapolation to humans. Recorded as
          PARTIAL because it states a possibility rather than demonstrating the
          human case, which is precisely the mismatch this discussion records.
      - reference: PMID:11850474
        reference_title: >-
          Cortical focus drives widespread corticothalamic networks during
          spontaneous absence seizures in rats.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Nonlinear association analysis revealed a consistent cortical "focus"
          within the peri-oral region of the somatosensory cortex.
        explanation: >-
          Identifies the specific rodent anatomical locus whose human counterpart
          is in question.
      - reference: PMID:41531116
        reference_title: >-
          Syndrome-specific and familial imaging traits in juvenile absence
          epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Gray matter volume was reduced in sensorimotor regions and in the left
          inferior and middle frontal gyri in patients.
        explanation: >-
          The best available human JAE structural imaging shows distributed
          sensorimotor and frontal change rather than a discrete generator,
          illustrating the gap between the rodent focus and human data. PARTIAL
          because structural volumetry cannot localize seizure onset.
  - discussion_id: cacna1h_disputed_gene_disease_validity
    kind: CONTROVERSY
    status: OPEN
    prompt: >-
      Given that ClinGen has reclassified CACNA1H as a disputed epilepsy gene,
      should CACNA1H be retained in the JAE model at all, and if so on what
      footing?
    attaches_to:
      - pathophysiology#Polygenic Susceptibility to Generalized Absence Epilepsy
      - pathophysiology#Altered Thalamic Low-Threshold Calcium Bursting
    rationale: >-
      CACNA1H encodes Cav3.2, the very T-type channel that carries the thalamic
      low-threshold current this entry models, so the gene is mechanistically
      attractive. It was reported in a childhood absence epilepsy cohort in 2003
      and subsequently entered commercial epilepsy gene panels. A 2020
      reassessment found that no published or ClinVar CACNA1H variant would meet
      ACMG criteria for pathogenic or likely pathogenic, that large exome studies
      show no enrichment of rare or de novo CACNA1H variants in epilepsy cohorts
      relative to controls, and that Cacna1h knockout mice do not seize. ClinGen
      classified the gene-disease relationship as disputed. The residual
      possibility is that CACNA1H acts as a modifier rather than a monogenic
      cause, which is exactly what the GAERS rat suggests, where a Cacna1h variant
      accounts for roughly a third of the variance in seizure frequency.

      That choice has been made here rather than inherited from legacy panels.
      The gene is retained with relationship_type MODIFIER, not SUSCEPTIBILITY.
      The refutation of monogenic causation is carried directly as REFUTE
      evidence, and the surviving modifier role alongside it as PARTIAL, sourced
      to the GAERS observation above. Removal was rejected because Cav3.2 is the
      T-type channel this entry's whole thalamic-bursting mechanism runs on, so
      deleting it would leave that mechanism attributed to no gene at all; a
      demoted typing that carries both the refutation and what survived it is the
      more honest record.

      The discussion stays OPEN because the science is unsettled, not because the
      curation decision is. ClinGen's disputed classification stands, the modifier
      role rests on rodent data, and the experiments below are what would resolve
      it.
    proposed_experiments:
      - experiment_id: exp_cacna1h_common_variant_burden_jae
        name: CACNA1H variant burden in syndrome-resolved IGE cohorts
        description: >-
          Burden and common-variant association testing of CACNA1H in large
          idiopathic generalized epilepsy cohorts that are resolved to ILAE 2022
          syndrome level, so that JAE is analysed separately from childhood
          absence epilepsy rather than pooled.
        decision_criterion: >-
          A significant burden or association confined to a syndrome stratum would
          justify retaining CACNA1H as a susceptibility contributor; a null result
          across strata would justify removing it from the model.
      - experiment_id: exp_cacna1h_modifier_effect_human
        name: Test of CACNA1H as a seizure-severity modifier in humans
        description: >-
          Test whether CACNA1H genotype modifies seizure frequency, drug response,
          or age of onset among patients who already carry an established epilepsy
          risk background, mirroring the modifier effect observed in the GAERS
          rat.
        decision_criterion: >-
          A reproducible genotype-severity relationship would support recuration
          of CACNA1H as a modifier rather than a susceptibility or causal gene.
    evidence:
      - reference: PMID:32227660
        reference_title: CACNA1H variants are not a cause of monogenic epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          the current status of CACNA1H as a monogenic cause of epilepsy is
          controversial, highlighted by ClinGen's recent reclassification of
          CACNA1H as disputed
        explanation: >-
          Documents that the controversy is formally recognized by ClinGen, which
          is what makes this a curation decision rather than a settled fact.
      - reference: PMID:32227660
        reference_title: CACNA1H variants are not a cause of monogenic epilepsy.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          in support of Cav3.2 contributing to seizure susceptibility as a
          modifier
        explanation: >-
          Preserves the surviving modifier hypothesis from the same analysis that
          refutes the monogenic claim, which is the alternative framing this
          discussion asks curators to weigh.
  - discussion_id: jae_cae_syndrome_boundary
    kind: KNOWLEDGE_GAP
    status: OPEN
    prompt: >-
      Does the age-of-onset boundary that separates juvenile absence epilepsy from
      childhood absence epilepsy mark a real mechanistic discontinuity, or is it a
      convenient cut through a single continuous absence-epilepsy spectrum?
    attaches_to:
      - pathophysiology#Polygenic Susceptibility to Generalized Absence Epilepsy
    rationale: >-
      The two syndromes are separated primarily by age of onset around puberty,
      and they share the thalamocortical mechanism, the EEG signature, and much of
      their candidate genetics. Yet they differ substantially in the things
      patients care about: absence frequency, generalized tonic-clonic burden, and
      the probability of remission. Nothing currently in the model explains why
      the same circuit lesion should produce a self-limiting pyknoleptic illness
      when it declares at age six and a persistent tonic-clonic-dominant illness
      when it declares at age twelve. Candidate explanations are different
      underlying genetic architecture, a pubertal endocrine or maturational
      modifier acting on an identical substrate, or an artefact of where the ILAE
      drew the line. JAE-specific imaging offers a partial handle: patients differ
      from controls in sensorimotor and frontal grey matter, and one trait, dorsal
      midcingulate volume, is shared with unaffected siblings, which suggests a
      heritable trait marker separable from the disease state. This gap matters
      for curation because it determines whether dismech should carry two
      mechanistically distinct entries or one entry with an onset-stratified
      model.
    proposed_experiments:
      - experiment_id: exp_cae_jae_shared_polygenic_architecture
        name: Genetic-correlation analysis between CAE and JAE
        description: >-
          Estimate the genetic correlation between syndrome-resolved childhood
          absence epilepsy and juvenile absence epilepsy cohorts, and test whether
          age of onset behaves as a continuous polygenic trait or as a mixture of
          two distinct liability distributions.
        decision_criterion: >-
          A genetic correlation near unity with continuous onset liability would
          favour a single spectrum; distinguishable architectures would support
          two mechanistically separate entries.
      - experiment_id: exp_pubertal_modifier_absence_onset
        name: Pubertal endocrine modifier study in absence epilepsy
        description: >-
          Prospective study of children with absence epilepsy through puberty,
          relating pubertal staging and sex-steroid trajectories to change in
          absence frequency, emergence of generalized tonic-clonic seizures, and
          remission.
        decision_criterion: >-
          If pubertal transition predicts the shift toward the JAE phenotype in
          children who began with a CAE phenotype, a maturational modifier acting
          on a shared substrate is supported over distinct diseases.
    evidence:
      - reference: PMID:35503716
        reference_title: >-
          ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:
          Position statement by the ILAE Task Force on Nosology and Definitions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          We provide updated diagnostic criteria for these IGE syndromes
          determined by the expert consensus opinion of the ILAE's Task Force on
          Nosology and Definitions
        explanation: >-
          Establishes that the syndrome boundaries in question are set by expert
          consensus criteria, which is precisely why their mechanistic status is
          an open question rather than a measured finding.
      - reference: PMID:41531116
        reference_title: >-
          Syndrome-specific and familial imaging traits in juvenile absence
          epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          increased gray matter volume in the dorsal midcingulate cortex was
          present in both patients and their siblings relative to controls
        explanation: >-
          Identifies a familial imaging trait present in unaffected siblings,
          offering a candidate endophenotype that could be tested for
          syndrome-specificity. PARTIAL because the study was not designed to
          compare JAE against childhood absence epilepsy directly.

📚

References & Deep Research

References

2

PMID:35503716

ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions.

No top-level findings curated for this source.

PMID:32437558

Clinical and experimental insight into pathophysiology, comorbidity and therapy of absence seizures.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

Juvenile Absence Epilepsy — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-opus-5[1m] 42 citations 2026-08-04T23:09:15.631121

Juvenile Absence Epilepsy — Comprehensive Research Report

Target: Juvenile Absence Epilepsy (JAE) · MONDO:0800453 (verified locally against sqlite:obo:mondo) · Category: Complex/multifactorial

⚠️ Read this before you paste anything into YAML

sup — quick housekeeping before the science. This report was assembled from live web search + fetch, and a chunk of the "quotes" below came back through a summarizing layer rather than as raw abstract text. That means some of them are paraphrases wearing quotation marks, which is exactly the failure mode dismech's reference validator exists to catch. It's the same problem as a PCR product that looks like the right band on a gel but is actually primer-dimer — plausible shape, wrong molecule.

So:

Snippets marked [VERBATIM] came back as complete abstract text and are very likely exact. Still run them through just fetch-reference + just validate-references.
Everything else marked [PARAPHRASE — DO NOT QUOTE] must be replaced with a real quote pulled from the cached abstract, or dropped.
Ontology terms marked ✓OAK were verified locally in this worktree against the OBO SQLite adapters. Terms marked ⚠unverified are suggestions only.

1. Disease Information

Overview

Juvenile absence epilepsy is one of four syndromes the ILAE recognizes as idiopathic generalized epilepsies (IGEs), which sit inside the broader bucket of genetic generalized epilepsies (GGEs). The other three are childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA).

The core picture: an otherwise neurologically normal adolescent starts having absence seizures around puberty, and — unlike in childhood absence epilepsy — those absences are infrequent rather than dozens-to-hundreds per day, and generalized tonic-clonic seizures show up in the great majority of patients. Think of CAE and JAE as the same instrument played at different tempos: CAE is a stuttering metronome, JAE is a slower, heavier bell that also rings the whole body.

Primary source — the ILAE nosology position statement:

[VERBATIM] "In 2017, the International League Against Epilepsy (ILAE) Classification of Epilepsies described the 'genetic generalized epilepsies' (GGEs), which contained the 'idiopathic generalized epilepsies' (IGEs). The goal of this paper is to delineate the four syndromes comprising the IGEs, namely childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic seizures alone. … Patients that do not fulfill criteria for one of these syndromes, but that have one, or a combination, of the following generalized seizure types: absence, myoclonic, tonic-clonic and myoclonic-tonic-clonic seizures, with 2.5–5.5 Hz generalized spike-wave should be classified as having GGE. Recognizing these four IGE syndromes as a special grouping among the GGEs is helpful, as they carry prognostic and therapeutic implications." — Hirsch E, French J, Scheffer IE, et al. Epilepsia 2022;63(6):1475–1499. PMID:35503716, DOI 10.1111/epi.17236. (Note: not open access — Europe PMC reports no PMCID.)

Identifiers

Resource	Identifier
MONDO	MONDO:0800453 — `juvenile absence epilepsy` (✓OAK)
OMIM	607631 — EPILEPSY, JUVENILE ABSENCE, SUSCEPTIBILITY TO, 1; EJA1 (EFHC1, 6p12)
OMIM	607628 — EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 11; EIG11 (contains EJA2 / CLCN2, 3q26) — see the retraction caveat in §4
ICD-10	G40.A (absence epilepsy syndrome; G40.A0/G40.A1 intractability/status modifiers). ⚠ verify against a current ICD release — historically JAE was coded under G40.3 (generalized idiopathic epilepsy)
ICD-11	8A61.1 Absence epilepsies (juvenile absence epilepsy is a subordinate entity) — ⚠ verify code against the current ICD-11 MMS browser
MeSH	D004832 "Epilepsy, Absence" (no JAE-specific MeSH descriptor exists)
Orphanet	JAE is covered under ORPHA entries for idiopathic generalized epilepsy; ⚠ a dedicated ORPHA code should be confirmed via `just structured-rebuild-orphanet` / Orphadata rather than guessed
epilepsydiagnosis.org	`syndrome/jae-overview.html` (ILAE's own syndrome portal)

Synonyms

Juvenile absence epilepsy (preferred)
JAE
Absence epilepsy of adolescence / adolescent-onset absence epilepsy
"Non-pyknoleptic absence epilepsy" (historical, contrasting with CAE's pyknolepsy = dense/clustered absences)
Janz–Christian "juvenile absence" (historical eponym usage; use with care)

Data provenance character

Almost everything here is aggregated disease-level knowledge — ILAE consensus syndrome definitions, hospital-based retrospective cohorts, and case-series literature. Two exceptions worth noting for dismech:

EHR/registry-derived, individual-patient level: the Danish national-registry cohort (PMID:35595971) links individual JAE cases to school grades and prescription redemptions.
Genotype-level population data: the ILAE Consortium GWAS (PMID:37653029) is individual-genotype based but reports at the GGE-subtype level.

2. Etiology

Causal architecture in one sentence

JAE is complex/polygenic, not Mendelian. It behaves like a threshold trait: lots of common variants of small effect, plus occasional rare high-impact variants (most importantly SLC2A1), summing to a thalamocortical circuit that is too eager to oscillate.

Genetic risk factors

Common-variant / polygenic contribution — the strongest modern evidence:

[VERBATIM] "Epilepsy is a highly heritable disorder affecting over 50 million people worldwide, of which about one-third are resistant to current treatments. Here we report a multi-ancestry genome-wide association study including 29,944 cases, stratified into three broad categories and seven subtypes of epilepsy, and 52,538 controls. We identify 26 genome-wide significant loci, 19 of which are specific to genetic generalized epilepsy (GGE). We implicate 29 likely causal genes underlying these 26 loci. SNP-based heritability analyses show that common variants explain between 39.6% and 90% of genetic risk for GGE and its subtypes. Subtype analysis revealed markedly different genetic architectures between focal and generalized epilepsies. Gene-set analyses of GGE signals implicate synaptic processes in both excitatory and inhibitory neurons in the brain. Prioritized candidate genes overlap with monogenic epilepsy genes and with targets of current antiseizure medications. Finally, we leverage our results to identify alternate drugs with predicted efficacy if repurposed for epilepsy treatment." — International League Against Epilepsy Consortium on Complex Epilepsies. Nat Genet 2023;55:1471–1482. PMID:37653029, DOI 10.1038/s41588-023-01485-w.

That "39.6% to 90%" range is the single most important etiologic number for a JAE entry: common variation dominates, and 19 of 26 loci are GGE-specific rather than shared with focal epilepsy. The genetic architecture of JAE is a chorus, not a soloist.

Rare/monogenic contributions — see §4 for gene-by-gene detail. Headline: SLC2A1 (GLUT1 deficiency) is the one genuinely actionable monogenic cause hiding inside absence-epilepsy cohorts.

Family history: family history of epilepsy is common in JAE probands. StatPearls reports family history of epilepsy in 41.8% and parental consanguinity in 40.3% — but ⚠ that consanguinity figure almost certainly reflects a specific regional cohort rather than JAE generally, and should not be generalized into a dismech entry without tracing the primary source.

Environmental / non-genetic risk factors

There are no established environmental causes of JAE. What exists are well-documented seizure precipitants in an already-genetically-susceptible person:

Sleep deprivation — classic and strongly associated with GTCS breakthrough in IGE broadly
Hyperventilation — the most reliable clinical provocateur of absences; 3 minutes of good hyperventilation failing to produce generalized spike-wave makes ongoing absence seizures unlikely (per the ILAE syndrome portal)
Photic stimulation — relevant in a minority (see §3)
Alcohol / withdrawal, stress, non-adherence, menstrual cycle
Aggravating drugs — this is the important one and is genuinely mechanistic, not merely behavioral: sodium-channel blockers and GABAergic drugs that raise thalamic tonic inhibition worsen absences (carbamazepine, oxcarbazepine, phenytoin, gabapentin, pregabalin, vigabatrin, tiagabine)

Protective factors

Genetic: none established. No protective allele has been convincingly reported for JAE. (Contrast with the abundant literature on susceptibility loci — this is a genuine asymmetry in the field.)
Environmental/behavioral: sleep hygiene, adherence, avoidance of the aggravating drugs above, and — in the specific GLUT1-deficient subgroup — ketogenic diet, which is arguably the only truly "mechanism-corrective" intervention in the whole absence-epilepsy space.

Gene–environment interaction

The best-characterized GxE in JAE is pharmacogenetic rather than toxicological: an SLC2A1-positive patient responds to ketogenic diet in a way a non-carrier does not, and a POLG-variant carrier exposed to valproate risks fatal hepatotoxicity (§12). These are the interactions that change clinical decisions. ⚠ Classical toxin/pollutant GxE data for JAE: not available — flag as a knowledge gap.

3. Phenotypes

3.1 Absence seizures (the defining feature)

Attribute	Value
Frequency among affected	~100% (definitional)
Onset	Adolescent/peripubertal; range 8–20 y, peak 9–13 y (ILAE syndrome portal); StatPearls gives mean onset 12.3 ± 2.8 y; a 58-patient Chinese cohort gives 11.86 ± 3.87 y (PMID:40945312)
Severity	Moderate — impairment of awareness is typically less complete than in CAE
Progression	Episodic; often improves with treatment, but frequently lifelong
Character	Non-pyknoleptic: typically fewer than one per day, versus the tens-to-hundreds daily of CAE. This is the clinical discriminator.
Duration	Longer than CAE absences (often >10 s; reported up to ~30 s)
Semiology extras	Mild eyelid/perioral myoclonus during the absence; oral/manual automatisms, classically emerging ~6–10 s after EEG discharge onset

HPO suggestions: - HP:0002121 Generalized non-motor (absence) seizure ✓OAK — the correct primary term - HP:0011147 Typical absence seizure ✓OAK — use for the specific typical-absence claim - HP:0011149 Absence seizure with eyelid myoclonia ✓OAK — only if eyelid myoclonia is documented; note this is also the defining feature of Jeavons syndrome, a differential, so use carefully - HP:0032678 Eyelid myoclonia seizure ✓OAK

⚠ Note for curators: HP:0002121's label is "Generalized non-motor (absence) seizure", not "Absence seizure." Don't write the colloquial label into term.label.

3.2 Generalized tonic-clonic seizures

Attribute	Value
Frequency	79–95% of JAE patients (StatPearls) — this high fraction is the second key discriminator from CAE
Onset	Usually after absence onset, but can precede it
Timing	Frequently on awakening; sleep-deprivation-sensitive
Prognostic weight	Presence of GTCS predicts substantially worse seizure-freedom outcomes (§11)

HPO: HP:0002069 Bilateral tonic-clonic seizure ✓OAK

3.3 Myoclonic seizures

Attribute	Value
Frequency	21–39% (StatPearls)
Nosological caution	Under ILAE 2022, prominent myoclonic seizures are exclusionary for JAE except for subtle myoclonus occurring during an absence — their presence pushes the diagnosis toward JME

HPO: HP:0002123 Generalized myoclonic seizure ✓OAK; HP:0032794 Myoclonic seizure ✓OAK

3.4 Absence status epilepticus

Attribute	Value
Frequency	Commonly cited at ~20% in JAE — JAE is among the syndromes with the highest rate of typical absence status. Typical absence status is reported in 10–30% of IGE-with-absences overall, versus only 6.7% in JME
Character	Prolonged confusional state lasting ≥10 minutes to hours (rarely days)
QoL impact	High — presents as prolonged altered mental status, frequently misdiagnosed as psychiatric or toxic-metabolic encephalopathy

HPO: HP:0002133 Status epilepticus ✓OAK ⚠ [PARAPHRASE — DO NOT QUOTE] the "~20%" figure; trace it to a primary series (Agathonikou/Panayiotopoulos-lineage literature) before curating a frequency.

3.5 Convulsive status epilepticus

~6% (StatPearls) ⚠ paraphrased figure.

3.6 Cognitive, academic, and psychiatric phenotypes

This is the part clinicians historically under-weighted, and where the strongest recent population data live.

Danish national registry cohort — Boesen MS, Børresen ML, Christensen SK, et al. J Neurol 2022;269(9). PMID:35595971, DOI 10.1007/s00415-022-11147-2. Cohort: 92 JAE cases, 190 JME, 27 GTCA, 15,084 non-neurological chronic-disease controls, plus population controls.

Reported for JAE: ~2× hazard for special-needs education vs. age-matched population controls; lower grade point averages in secondary and high school; 15% fewer JAE patients attended high school; elevated redemption of sleep medication and ADHD medication vs. chronic-disease controls. ⚠ [PARAPHRASE — DO NOT QUOTE] — all of the above came through a summarizer. Fetch and re-quote.

Other reported figures (all ⚠ paraphrase-level, StatPearls/secondary): - Mild-to-severe academic underachievement in 65% - Comorbidities affecting learning in 38% - Psychiatric comorbidity in 43% of JAE - Cognitive deficits occur even without breakthrough seizures — i.e., they are not simply a seizure-burden readout

HPO suggestions: HP:0007018 Attention deficit hyperactivity disorder ✓OAK · HP:0000739 Anxiety ✓OAK · HP:0000716 Depression ✓OAK · HP:0002360 Sleep disturbance ✓OAK

Anxiety has direct prognostic weight — see the Datta cohort in §8/§11.

3.7 Antecedent history

Development, neurological exam, head size, and cognition normal prior to onset (ILAE syndrome portal) — this is close to a mandatory feature
Prior febrile seizures occasionally reported — HP:0002373 Febrile seizure (within the age range of 3 months to 6 years) ✓OAK

3.8 EEG phenotype (laboratory/electrophysiological)

Feature	Finding
Background	Normal. Generalized slowing does not occur; focal slowing should prompt search for a structural lesion
OIRDA	Occipital intermittent rhythmic delta activity may be seen
Ictal discharge	Regular 3–5.5 Hz generalized spike-wave or polyspike-wave with absences
Interictal	Generalized spike-wave, fragments of GSW, or polyspike-wave; focal spikes may occur but should not consistently localize
Exclusionary	Slow spike-wave <2.5 Hz is absent — its presence suggests an alternative diagnosis (e.g., Lennox-Gastaut)
vs. CAE	JAE discharges are slightly faster, more fragmented, and more disorganized than CAE's regular 3 Hz
Activation	Hyperventilation provokes GSW and clinical absences; 3 min of successful hyperventilation without GSW makes absence seizures unlikely. Sleep deprivation, drowsiness, and sleep enhance abnormalities, though spike-wave fragments in sleep
Photoparoxysmal response	Low in JAE — reported around 7.5% in one IGE-syndrome series and 10% (2/20) in another
ILAE criterion	An ictal EEG is not required for diagnosis, provided the interictal study shows paroxysms of 3–5.5 Hz GSW during wakefulness

HPO suggestions: HP:0011198 EEG with generalized epileptiform discharges ✓OAK · HP:0012000 EEG with generalized spikes ✓OAK · HP:0011182 Interictal epileptiform activity ✓OAK ⚠ Do not use HP:0010845 for spike-wave — its real label is EEG with generalized slow activity (✓OAK), a different claim entirely.

3.9 Quality-of-life impact

Not formally quantified with EQ-5D/SF-36/PROMIS in JAE-specific literature (gap). Documented functional impacts: - Driving restrictions — a live issue in GGE; see PMID:38500008 (J Child Neurol 2024, "Clearance for Driving in Genetic Generalized Epilepsy") - Educational attainment — the Danish cohort above - Self-esteem, aggression, body perception, alexithymia in adolescent IGE — PMID:41857384 (Eur J Pediatr 2026) - Lifelong medication burden — most JAE patients require indefinite treatment

4. Genetic / Molecular Information

4.1 The honest framing

There is no single causal gene for JAE. OMIM's "EJA1/EJA2" entries are susceptibility loci, and one of the two rests on a retracted paper. A dismech entry should model JAE as polygenic with a small monogenic tail, and should explicitly record the retraction — this is exactly the kind of thing a knowledge base should get right where secondary sources get it wrong.

4.2 Named susceptibility genes

EFHC1 (HGNC:16406 ⚠verify; OMIM *608815; 6p12) — "EJA1", OMIM #607631

Susceptibility to juvenile absence epilepsy-1 is conferred by variation in EFHC1. The gene was originally established for JME:

Suzuki T, Delgado-Escueta AV, Aguan K, et al. "Mutations in EFHC1 cause juvenile myoclonic epilepsy." Nat Genet 2004;36:842–849. PMID:15258581 ⚠verify PMID. Heterozygous missense variants (229C→A, 662G→A, 685T→C, 628G→A, 757G→T) cosegregating in six Mexican JME families, with reduced penetrance (unaffected carriers present). Functional claim: variants reversed EFHC1-induced neuronal cell death and the EFHC1-dependent increase in R-type Ca²⁺ current.
Critical caveat: a formal ACMG/NHGRI reanalysis concluded the causality evidence is weak — Subaran/Bailey et al., "EFHC1 variants in juvenile myoclonic epilepsy: reanalysis according to NHGRI and ACMG guidelines for assigning disease causality," Genet Med 2016. PMID:27467453. Curate EFHC1 as DISPUTED/limited, not established.

CLCN2 (OMIM *600570; 3q26) — "EJA2", under OMIM #607628 — RETRACTED PRIMARY EVIDENCE

This one needs a loud flag in any KB entry:

Original: Haug K, et al. "Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies." Nat Genet 2003. PMID:12612585.
Retracted in Nat Genet 2009;41:1043. Grounds: far fewer clinically affected individuals than reported, substantially different pedigree structures and phenotypes, and asymptomatic mutation carriers on re-examination — refuting the claimed complete cosegregation. The authors stated they regretted failing to recognize that important family data were false before publication.
Subsequent dispute: Niemeyer et al., "No evidence for a role of CLCN2 variants in idiopathic generalized epilepsy," Nat Genet 2010;42:3, arguing lack of functional consequence — against Kleefuss-Lie et al. (Nat Genet 2009;41:954) who argued some of the original work retained merit.
Note CLCN2 is a real disease gene — for CLCN2-related leukoencephalopathy (GeneReviews, NBK326661) — which is a different phenotype and a classic named-entity trap.

CACNA1H (Cav3.2 T-type calcium channel; 16p13.3) — the mechanistically satisfying one

Heron SE, Khosravani H, Varela D, et al. "Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants." Ann Neurol 2007;62(6):560–568. PMID:17696120, DOI 10.1002/ana.21169. >100 heterozygous variants (19 novel) across 240 IGE patients; 9 of 11 tested variants altered channel properties in a gain-of-function manner.
Interpretive line worth curating verbatim-ish (⚠ re-quote from abstract): variants contribute to susceptibility but are not sufficient to cause epilepsy on their own. This is the textbook "susceptibility modifier, not driver" pattern.
Variant class: missense, germline, gain-of-function.
Note the correspondence with the GAERS rat model (§15), which carries a gain-of-function Cacna1h R1584P — a rare instance where the human susceptibility gene and the flagship animal model converge on the same channel.

SLC2A1 / GLUT1 (1p34.2) — the actionable rare cause

This is the gene that changes management, because it makes ketogenic diet a mechanism-directed therapy.

Mullen SA, Suls A, De Jonghe P, Berkovic SF, Scheffer IE. "Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency." Neurology 2010;75:432–440. PMID:20574033. Two kindreds (9 individuals/3 generations; 6/2 generations). Of 15 SLC2A1 mutation carriers, 12 developed epilepsy; absence seizures predominated (10/12) with onset spanning 3 to 34 years. Phenotypes: IGE-with-absence 8/12, myoclonic-astatic 2/12, focal 2/12. Paroxysmal exertional dyskinesia in 7, often subtle and previously undiagnosed. Two carriers unaffected (incomplete penetrance).
Arsov T, Mullen SA, Damiano JA, et al. "Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1 deficiency." Epilepsia 2012;53(12). PMID:23106342. 55 patients with absence onset before age 4; mutations in 7 (13%) — five missense, one single-amino-acid in-frame deletion, one two-exon deletion. Pooled across studies: ~12% of 89 patients. Conclusion: SLC2A1 analysis should be strongly considered in early-onset absence epilepsy given treatment and genetic-counseling implications.
Larsen J, et al. Epilepsia 2015. PMID:26537434 — role of SLC2A1 in myoclonic-astatic and absence epilepsy; population frequency of SLC2A1 mutations in Denmark estimated ~1:83,000; true GLUT1DS prevalence estimated at least 1:24,000. None of 120 MAE patients carried SLC2A1 mutations in that series.
JAE-specific caution: the strongest GLUT1 yield is in early-onset absence epilepsy (onset <4 y), not classic peripubertal JAE. Mullen's kindreds show absence onset up to age 34, so JAE-range onset does occur — but a dismech entry should not imply a 10% GLUT1 yield in typical JAE. Mullen et al. also published "GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy" (Neurology 2011) — the deflationary companion paper.

Other reported susceptibility genes (all weak-to-moderate evidence; curate as SUSCEPTIBILITY, not causal):

GRIK1 (allelic variants conferring susceptibility — cited in StatPearls for JAE), ADGRV1 (familial GGE; see PMC8567843), CACNA1A, CACNB4, GABRG2, GABRA1, GABRB3. The GABA-A receptor subunit genes are more firmly established in CAE than in JAE.

4.3 Inheritance / mode

Multifactorial/polygenic for the syndrome as a whole
Autosomal dominant with incomplete penetrance for the SLC2A1 familial subgroup
Rare familial aggregation with syndrome-shifting within families — a JAE proband may have a JME or GTCA sibling, consistent with shared genetic architecture across IGE

4.4 Allele frequency, somatic/germline, functional consequence

All established variants are germline. No somatic contribution reported (not applicable for JAE).
SLC2A1: loss of function (haploinsufficiency of the blood-brain-barrier glucose transporter)
CACNA1H: gain of function (enhanced T-type current)
EFHC1: originally proposed loss of a pro-apoptotic/Ca²⁺-modulatory function — now disputed
gnomAD frequencies: ⚠ not retrieved in this pass; should be pulled per-variant before curation

4.5 Modifier genes, epigenetics, chromosomal abnormalities

Modifiers: CACNA1H is arguably best modeled as a modifier rather than a driver. No formally validated modifier locus for JAE.
Epigenetics: ⚠ no JAE-specific methylation/histone data found. Genuine knowledge gap.
Chromosomal abnormalities: none characteristic. JAE is not a CNV syndrome; a pathogenic CNV or abnormal microarray should prompt reconsideration of the diagnosis. (Contrast with 15q13.3/16p13.11/15q11.2 microdeletions in GGE broadly — those are enriched in GGE cohorts and are worth a note, but they are not JAE-defining.)

5. Environmental Information

Environmental toxicants: no established etiologic exposure. Not applicable / no evidence.
Lifestyle factors: sleep deprivation, alcohol, and non-adherence are seizure precipitants, not causes. Photic environments (strobes, some video content) matter for the photosensitive minority.
Infectious agents: not applicable. JAE is by definition idiopathic; an infectious or inflammatory etiology excludes the syndrome.
Nutritional: the only nutrition-mechanism link is the ketogenic diet as therapy in GLUT1 deficiency, where ketone bodies bypass the defective glucose transporter — a metabolic detour around a broken bridge.

6. Mechanism / Pathophysiology

6.1 The causal chain, upstream to downstream

Here's the mechanism in the shape dismech wants — a chain of nodes with a clear direction of travel:

Polygenic + rare variant load (CACNA1H GoF, SLC2A1 LoF, GABA-A subunit variants,
26 GWAS loci enriched for synaptic genes in excitatory AND inhibitory neurons)
↓  [MOLECULAR]
Altered ion-channel gating / synaptic transmission
   — enhanced low-voltage-activated (T-type) Ca²⁺ current in thalamic neurons
   — altered GABA-A/GABA-B mediated inhibition
↓  [CELLULAR]
Hyperpolarization → de-inactivation of T-type channels → rebound low-threshold
Ca²⁺ spikes → burst firing in thalamocortical relay neurons and thalamic
reticular nucleus neurons
↓  [CELLULAR/TISSUE]
Reciprocal cortico-thalamo-cortical loop entrainment;
cortical initiation focus recruits the loop within ~ms
↓  [TISSUE]
Bilaterally synchronous 3–5.5 Hz generalized spike-wave discharge
↓  [ORGANISM]
Impairment of awareness / behavioral arrest (absence seizure);
when the same network fails to terminate → absence status epilepticus;
when a different recruitment mode dominates → GTCS

6.2 The thalamocortical oscillator — the core machinery

The circuit has three players: cortical glutamatergic pyramidal neurons, thalamocortical relay neurons, and the GABAergic neurons of the thalamic reticular nucleus (nRT). Together they form a resonant loop that normally generates sleep spindles; in absence epilepsy the same loop slips into a pathological 3-Hz mode. It's the difference between a bell rung once and a bell that won't stop.

The T-type calcium channel is the timing element. After depolarization, T-type channels briefly pass Ca²⁺ then inactivate; reactivation requires sustained hyperpolarization, which GABA-B receptor activation supplies. That non-linear coupling between GABA-B-mediated hyperpolarization and T-type de-inactivation is what sets the oscillation frequency — and it's why GABA-B agonism worsens absences while GABA-A-directed benzodiazepines can help.

Channel-subtype distribution: - Cav3.1 (CACNA1G) — highly expressed in thalamocortical relay neurons - Cav3.2 (CACNA1H) and Cav3.3 (CACNA1I) — mainly in nRT neurons

Key references: - Crunelli V, Leresche N. "Childhood absence epilepsy: genes, channels, neurons and networks." Nat Rev Neurosci 2002;3(5):371–382. PMID:11988776, DOI 10.1038/nrn811. [VERBATIM] — "Childhood absence epilepsy is an idiopathic, generalized non-convulsive epilepsy with a multifactorial genetic aetiology. Molecular-genetic analyses of affected human families and experimental models, together with neurobiological investigations, have led to important breakthroughs in the identification of candidate genes and loci, and potential pathophysiological mechanisms for this type of epilepsy." - Powell KL, Cain SM, Snutch TP, O'Brien TJ. "The role of T-type calcium channel genes in absence seizures." PMID:24847307 (Front Neurol/review; PMC4023043) - Tringham E, et al. "T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures." Sci Transl Med 2012. PMID:22344687 — pharmacological proof-of-mechanism.

6.3 Cortical focus vs. thalamic pacemaker — a real, curatable controversy

Two competing (now partly reconciled) models of where the discharge starts. This is a good candidate for dismech mechanistic_hypotheses:

Thalamic pacemaker model (CANONICAL, historical): nRT drives the loop; the thalamus is the metronome.
Cortical focus model (now dominant for rodent models): Meeren HKM, Pijn JPM, van Luijtelaar ELJM, Coenen AML, Lopes da Silva FH. "Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats." J Neurosci 2002;22(4):1480–1495. PMID:11850474. Nonlinear association analysis in WAG/Rij rats revealed a consistent cortical "focus" in the peri-oral region of somatosensory cortex; a cortical focus is the dominant factor initiating the paroxysmal oscillation within corticothalamic loops, with large-scale synchronization mediated by extremely fast intracortical spread. ⚠ re-quote from abstract before curating.
HUMAN_MODEL_MISMATCH flag: the cortical focus is established in rat genetic models (WAG/Rij, GAERS). Whether a discrete somatosensory-cortex focus exists in human JAE is not settled — human data point to frontal/thalamic network involvement without a single anatomically stereotyped focus. This is exactly the HUMAN_MODEL_MISMATCH discussion kind, not a plain knowledge gap.

Also: Sorokin JM, et al. / McCafferty C, et al. "Cortical drive and thalamic feed-forward inhibition control thalamic output synchrony during absence seizures." Nat Neurosci 2018 — a synthesis position: cortex drives, thalamus synchronizes.

6.4 Network-level and human neuroimaging findings

Default mode network / striatal networks — JAE-specific:

[VERBATIM] "Purpose: To explore the features of dynamic functional connectivity (dFC) variability of striatal-cortical/subcortical networks in juvenile absence epilepsy (JAE). Methods: We collected resting-state functional magnetic imaging data from 18 JAE patients and 28 healthy controls. The striatum was divided into six pairs of regions: the inferior-ventral striatum (VSi), superior-ventral striatum (VSs), dorsal-caudal putamen, dorsal-rostral putamen, dorsal-caudate (DC) and ventral-rostral putamen. We assessed the dFC variability of each subdivision in the whole brain using the sliding-window method, and correlated altered circuit with clinical variables in JAE patients. Results: We found altered dFC variability of striatal-cortical/subcortical networks in patients with JAE. The VSs exhibited decreased dFC variability with subcortical regions, and dFC variability between VSs and thalamus was negatively correlated with epilepsy duration. For the striatal-cortical networks, the dFC variability was decreased in VSi-affective network but increased in DC-executive network. The altered dynamics of striatal-cortical networks involved crucial nodes of the default mode network (DMN). Conclusion: JAE patients exhibit excessive stability in the striatal-subcortical networks. For striatal-cortical networks in JAE, the striatal-affective circuit was more stable, while the striatal-executive circuit was more variable. Furthermore, crucial nodes of DMN were changed in striatal-cortical networks in JAE." — Zhang T, Zhang Y, Ren J, et al. Epilepsy Behav 2023. PMID:37925871

EEG graph-theory network dynamics in drug-naïve JAE:

[VERBATIM] "Objective: We aimed to investigate the brain network activity during seizures in patients with untreated juvenile absence epilepsy. Methods: Thirty-six juvenile absence epilepsy (JAE) patients with a current high frequency of seizures (more than five seizures during a 2 h EEG examination) were included. … Results: Compared with the resting state of the HC group, the global efficiency, local efficiency, and clustering coefficients of the JAE group decreased in the inter-ictal state. In addition, the ictal state showed significantly increased global and local efficiency and clustering coefficients (p < 0.05) and a decreased small-world index and the shortest path length (p < 0.05) in the theta and alpha bands, compared to the remaining states within the JAE group. Moreover, subgroup analysis revealed that those JAE patients with typical 3 Hz discharges had upgraded global efficiency, local efficiency, and clustering coefficients in both delta and beta1 bands, compared to those JAE patients with non-3 Hz discharges during seizures. Conclusion: The present study supported the idea that the changes in the EEG brain networks in JAE patients are characterized by decreased global and local efficiency and clustering coefficient in the alpha band. Moreover, the onset of seizures is accompanied by excessively enhanced network efficiency. JAE patients with different ictal discharge patterns may have different functional network oscillations." — Tan L, Tang H, Luo H, et al. Front Neurol 2024;15:1340959. PMID:38550342

Structural + task-fMRI, with an endophenotype angle (2026, JAE-specific and syndrome-discriminating):

Xiao F, Caciagli L, Delazer L, et al. "Syndrome-specific and familial imaging traits in juvenile absence epilepsy." Epilepsia 2026. PMID:41531116. 23 JAE patients, 18 unaffected siblings, 28 controls. Reported: increased motor-cortex activation during an attention-only condition in patients vs. controls and siblings; reduced grey matter volume in sensorimotor and frontal regions; increased midcingulate grey matter volume as a possible familial (endophenotype) marker related to attentional vulnerability; and functional reorganization patterns distinct from JME. ⚠ [PARAPHRASE — DO NOT QUOTE].

This last one is genuinely valuable for a dismech entry because it separates JAE from JME at the imaging level and offers a heritable-trait node.

6.5 Metabolic mechanism (the GLUT1 branch)

In SLC2A1-related absence epilepsy the chain is different and cleaner:

SLC2A1 haploinsufficiency → reduced facilitated glucose transport across the
blood-brain barrier → chronic cerebral energy deficit (low CSF glucose) →
impaired inhibitory interneuron function / network instability → absence seizures
+ paroxysmal exertional dyskinesia + (variable) intellectual disability

Therapeutic corollary: ketone bodies bypass GLUT1, hence the ketogenic diet.

6.6 Immune, inflammatory, fibrotic, oxidative mechanisms

Not applicable. JAE has no established autoimmune, inflammatory, oxidative-stress, or tissue-destruction mechanism. There is no neurodegeneration, no gliosis, no cell death — this is a functional channelopathy-adjacent network disorder, and imaging/pathology are normal by definition. Any KB entry asserting inflammatory mechanism here would be over-reaching. (Recent Mendelian-randomization papers linking IL-6R and epilepsy subtypes — e.g. PMID:39165549 — are hypothesis-generating at best and should not be curated as mechanism.)

6.7 Omics

Transcriptomics/proteomics/single-cell/spatial for human JAE: ⚠ none found. Genuine gap. GWAS gene-set analysis implicates synaptic processes in both excitatory and inhibitory neurons (PMID:37653029) — that's the closest thing to a molecular signature.
Metabolomics: PMID:39629734 — "Metabolite Associations with Childhood and Juvenile Absence Epilepsy: A Bidirectional Mendelian Randomization Study" (Psychiatry Clin Psychopharmacol 2024). ⚠ MR study, COMPUTATIONAL evidence source, low weight.
Functional genomics screens (CRISPR/RNAi): none JAE-specific.

Suggested GO terms (all ✓OAK verified locally)

GO ID	Label	Use
GO:0090676	calcium ion transmembrane transport via low voltage-gated calcium channel	T-type current — the single best-fitting term
GO:0070588	calcium ion transmembrane transport	broader
GO:0015085	calcium ion transmembrane transporter activity	molecular function
GO:0051932	synaptic transmission, GABAergic	inhibitory arm
GO:0007214	gamma-aminobutyric acid signaling pathway	GABA-A/GABA-B signaling
GO:0042391	regulation of membrane potential	hyperpolarization/de-inactivation node
GO:0019228	neuronal action potential	burst firing
GO:1904659	D-glucose transmembrane transport	SLC2A1/GLUT1 branch
GO:0021794	thalamus development	developmental context (use sparingly)

7. Anatomical Structures Affected

Organ / system level

Body system: nervous system, exclusively
Primary organ: brain
Secondary organ involvement: none intrinsic. Secondary harms are injury-related (falls, trauma during GTCS) and treatment-related (liver, bone marrow, teratogenesis)

Structures

Structure	UBERON	Status	Role
Thalamus	UBERON:0001897 `dorsal plus ventral thalamus`	✓OAK	Oscillator hub
Thalamic reticular nucleus	⚠ needs lookup — UBERON search did not resolve cleanly in this pass; do NOT guess an ID	⚠	GABAergic pacemaker element; expresses Cav3.2/Cav3.3
Cerebral cortex	UBERON:0000956	✓OAK	Initiation/driving
Neocortex	UBERON:0001950	✓OAK
Somatosensory cortex	UBERON:0008930	✓OAK	Rodent cortical focus (peri-oral region) — model-organism finding, flag as such
Frontal cortex / midcingulate	⚠ needs lookup	⚠	Human imaging findings (Xiao 2026)
Striatum (ventral striatum, dorsal caudate, putamen subdivisions)	⚠ needs lookup	⚠	Zhang 2023 dFC findings
Blood-brain barrier	⚠ needs lookup	⚠	GLUT1 branch only

Cell types

Cell type	CL	Status	Role
Glutamatergic neuron	CL:0000679	✓OAK	Cortical drive; thalamocortical relay
GABAergic neuron	CL:0000617	✓OAK	nRT inhibitory pacemaker
Pyramidal neuron	CL:0000598	✓OAK	Cortical layer V/VI initiation
Cortical interneuron	CL:0008031	✓OAK	Feed-forward inhibition
Thalamocortical relay neuron	⚠ needs lookup (CL may lack a precise term)	⚠	Cav3.1-expressing burst generator
Microglial cell	CL:0000129	✓OAK	⚠ Do not use unless you have real evidence — there is no established microglial mechanism in JAE. Listed only so a curator doesn't reach for it reflexively.

Subcellular

Plasma membrane / voltage-gated calcium channel complex — the T-type channels
Presynaptic and postsynaptic membranes — GABAergic synapse
Endoplasmic reticulum — relevant only via the GAERS calnexin-trafficking mechanism (model organism) ⚠ GO cellular-component IDs not verified in this pass.

Lateralization

Bilateral and synchronous — this is definitional. The discharge is generalized from onset, bilaterally synchronous, and symmetric. Consistently lateralized or focal-onset discharges are an exclusionary/alert feature, though transient asymmetry and non-consistent focal spikes are permitted.

8. Temporal Development

Onset

Age range: 8–20 years; peak 9–13 years (ILAE syndrome portal)
Mean: 12.3 ± 2.8 y (StatPearls) and 11.86 ± 3.87 y (PMID:40945312)
Pattern: insidious. Absences are infrequent and subtle in JAE, so the diagnostic trigger is frequently the first GTCS rather than the absences — which are then discovered retrospectively. This is a clinically important asymmetry vs. CAE, where daily absences get noticed at school.
HPO onset: Juvenile onset ⚠ verify HP ID before use

The 8–11 year "watershed"

There's a genuine nosological grey zone where CAE, JAE, and JME overlap. The best study of it:

[VERBATIM] "Introduction: Absence seizures occur in various epilepsy syndromes, including childhood and juvenile absence epilepsy and juvenile myoclonic epilepsy. When children present with absence seizures at ages when syndromes overlap, initial syndrome designation is not always possible, making early prognostication challenging. For these children, the study objective is to determine clinical and initial electroencephalograph (EEG) findings to predict the development of generalized tonic-clonic seizures, which is a factor that affects outcome. Methods: Children with new-onset absence seizures between 8 and 11 years of age with at least 5 years of follow-up data were studied through the review of medical records and initial EEG tracings. Results: Ninety-eight patients were included in the study. The median age of absence seizure onset was 9 years (interquartile range [IQR] = 8.00, 10.00) and follow-up was 15 years (IQR = 13.00, 18.00). Forty-six percent developed generalized tonic-clonic seizures and 20% developed myoclonic seizures. On multiple regression analysis, a history of myoclonic seizures, anxiety, as well as bifrontal slowing and mild background slowing on initial EEG (P < .05) were associated with generalized tonic-clonic seizures. Although not statistically significant, a shorter duration of shortest EEG burst on baseline EEG was also associated with generalized tonic-clonic seizures. Conclusion: On initial EEG, bifrontal and background slowing and myoclonic seizures and anxiety are associated with developing generalized tonic-clonic seizures, which is of prognostic significance when early syndrome designation is difficult." — Datta AN, Crawford J, Wallbank L, Wong PKH. J Child Neurol 2023;38(8–9). PMID:37461321

Note the striking finding: anxiety — a psychiatric comorbidity — predicts GTCS development. Not a direction most people would guess.

Course and progression

Course pattern: episodic/recurrent seizures on a stable, non-degenerative substrate. JAE does not progress neurologically; there is no atrophy-driven decline. (⚠ Caveat: PMID:41604608, "Progressive Changes in Brain Morphology in People With Idiopathic Generalized Epilepsy," Neurology 2026, reports longitudinal morphometric change in IGE — worth curating as an emerging, non-clinical finding, not as clinical progression.)
Duration: chronic, frequently lifelong. This is the sharpest contrast with CAE, which usually remits in adolescence. JAE typically does not outgrow itself.
Evolution to JME: approximately 18% of JAE progresses to JME (StatPearls) ⚠ paraphrase — trace to primary source.
Seizure-type evolution: absences first, GTCS added later in most patients.

Critical windows

Puberty — the syndrome's onset window; hormonal and maturational timing is unexplained (gap)
Adolescence/early adulthood — highest risk period for sleep-deprivation-triggered GTCS, driving, and alcohol exposure
Female reproductive years — the window where valproate choice becomes irreversible in consequence (§12)
Post-seizure-freedom withdrawal window — see §11

9. Inheritance and Population

Epidemiology

Measure	Value	Source
Prevalence	~0.1 per 1,000 = 10 per 100,000	StatPearls ⚠ paraphrase
Share of childhood epilepsies	1–2%	StatPearls ⚠
Share of idiopathic generalized epilepsy	~15–20%	StatPearls ⚠
Sex ratio	Approximately 1:1 (male:female) — ILAE portal states it affects both sexes equally	ILAE syndrome portal
Absence-seizure incidence (all syndromes, context)	0.7–4.6 / 100,000 / yr general population; 6–8 / 100,000 in ages 0–15	secondary ⚠
Absence-seizure prevalence (context)	5–50 / 100,000 general population	secondary ⚠

Prevalence class for dismech Prevalence: BAND_1_5_PER_10000 with rate_per_100000: 10.0, measure_type: POINT_PREVALENCE, population: Worldwide. ⚠ The underlying 0.1/1,000 figure is secondary-source; ideally re-anchor on Orphanet epidemiology or a primary population study before curating.

Inheritance

Pattern: multifactorial / polygenic — this is the correct top-level inheritance_term. HPO Multifactorial inheritance / Polygenic inheritance (HP:0010982) ⚠ verify IDs.
Autosomal dominant with incomplete penetrance applies only to the SLC2A1 familial subgroup — model this as a subtype-level inheritance block, not disease-level. Mullen 2010: 15 carriers, 12 affected → penetrance ~80% in those kindreds.
Expressivity: highly variable — the same SLC2A1 variant produced IGE-with-absence, myoclonic-astatic epilepsy, and focal epilepsy within the same families, with absence onset spanning 3 to 34 years.
Anticipation: none reported. Not applicable (no repeat expansion).
Germline mosaicism: not reported for JAE.
Founder effects: none established for JAE. (EFHC1 JME variants were described in Mexican families — that's ascertainment, not a demonstrated founder effect.)
Consanguinity: StatPearls reports 40.3% parental consanguinity ⚠ — this is inconsistent with a polygenic dominant-ish model and almost certainly reflects a single regional cohort. Do not curate this without tracing it.
Carrier frequency: not applicable for a polygenic syndrome. For SLC2A1, Danish population frequency estimated ~1:83,000 (PMID:26537434).

Population demographics

Ethnic/geographic variation: none established. The GWAS was multi-ancestry but did not report JAE-specific ancestry effects.
Age distribution: onset concentrated 9–13 y; prevalent population skews adolescent-to-adult given the chronic course.
Sex: ~equal. ⚠ Some series report slight female predominance in IGE overall; the ILAE portal states equal for JAE, so use equal.

10. Diagnostics

Diagnosis is clinical + electroencephalographic. There is no biomarker.

ILAE 2022 diagnostic criteria (Hirsch 2022, PMID:35503716)

Mandatory: - Absence seizures (the defining seizure type) - 3–5.5 Hz generalized spike-wave on EEG. An ictal EEG is not required provided the interictal study shows paroxysms of 3–5.5 Hz GSW during wakefulness - Normal EEG background - Age at onset within the juvenile window (8–20 y, peak 9–13 y)

Exclusionary: - Myoclonic seizures — except for subtle myoclonus occurring during an absence (prominent myoclonus → JME) - Slow spike-wave <2.5 Hz - Generalized EEG background slowing - Abnormal neurological exam / developmental regression / abnormal structural imaging - Consistently localizing focal discharges

Alerts (do not exclude, but should trigger a rethink and further investigation): the ILAE framework notes that "the more alerts that are present, the less confident one can be about diagnosis of a specific syndrome." ⚠ The full mandatory/exclusionary/alert tables live in the paywalled Table for JAE in PMID:35503716 — fetch the actual table before curating a definitions block.

Electrophysiology (the diagnostic centerpiece)

Routine EEG with 3 minutes of hyperventilation — the single highest-yield test. Failure to provoke GSW after adequate hyperventilation makes ongoing absence seizures unlikely.
Intermittent photic stimulation — photoparoxysmal response in a minority (~7.5–10%)
Sleep-deprived EEG / prolonged video-EEG — for cases with normal routine EEG, and to characterize seizure frequency. Note PMID:38550342 used 2-hour video EEG with ≥5 seizures as an inclusion threshold.
24-hour ambulatory EEG — used as the endpoint measure in the brivaracetam trial (§12)
Emerging: wearable-device seizure counting (PMID:40116734, Epilepsia 2025, "Tailoring antiseizure treatment with a wearable device: A proof-of-concept study in absence epilepsy"); ultra-long-term subcutaneous EEG in drug-refractory IGE (PMID:41066224, Epilepsia 2026)

LOINC: EEG study ⚠ specific LOINC codes not retrieved; look up rather than guess.

Imaging

Normal by definition. MRI is typically negative; non-specific findings occasionally seen. An abnormal MRI showing a structural lesion excludes the syndrome. Research-grade quantitative MRI shows group-level differences (§6.4) but has no diagnostic role.

Laboratory tests

No diagnostic blood/urine test exists.
Lumbar puncture with paired CSF/plasma glucose — the one high-value lab test, and only when GLUT1 deficiency is suspected (early-onset absence, absence + paroxysmal exertional dyskinesia, absence + family history of movement disorder, drug-resistant absence). Low CSF glucose and low CSF:plasma glucose ratio.
Routine chemistry/CBC/LFTs are treatment-monitoring tests (valproate), not diagnostic.

Genetic testing

Test	Utility in JAE
*Targeted SLC2A1* testing**	The highest-yield genetic test, and the only one that reliably changes management. Arsov 2012 conclusion: SLC2A1 analysis "should be strongly considered" in early-onset absence epilepsy. Extend the indication to drug-resistant absence and absence + PED at any age.
Epilepsy gene panel	Reasonable in atypical, drug-resistant, or familial cases. Genes of interest: SLC2A1, CACNA1H, CACNA1A, CACNA1G, CACNB4, GABRG2, GABRA1, GABRB3, GRIK1, EFHC1 (interpret with the caveats in §4)
WES / WGS	Not routine. Consider for drug-resistant or syndromic presentations.
Chromosomal microarray	Low yield in typical JAE; a pathogenic CNV should prompt diagnostic reconsideration. Some value in GGE cohorts for 15q13.3 / 16p13.11 / 15q11.2 recurrent CNVs.
Karyotype / FISH / mtDNA / repeat expansion	Not indicated. No role in JAE.
Polygenic risk scores	Research only. The 2023 GWAS makes GGE PRS technically feasible but it is not clinically actionable for JAE.

Omics-based diagnostics

None validated. RNA-seq, proteomics, metabolomics, epigenomics, liquid biopsy: all not applicable to JAE diagnosis. Flag as gap rather than inventing utility.

Differential diagnosis — the ones that actually matter

Differential	Distinguishing features
Childhood absence epilepsy (CAE)	Younger onset (6–7 y); pyknoleptic (tens-to-hundreds of absences/day); shorter absences with more complete impairment; regular 3 Hz GSW; GTCS uncommon; high spontaneous remission
Juvenile myoclonic epilepsy (JME)	Prominent myoclonic jerks on awakening (exclusionary for JAE); polyspike-wave; higher photosensitivity
Epilepsy with GTCS alone (GTCA)	No absences
Eyelid myoclonia with absences (Jeavons)	Marked eyelid myoclonia, eye-closure sensitivity, high photosensitivity
Myoclonic absence epilepsy	Rhythmic myoclonus with tonic abduction during the absence
GLUT1 deficiency syndrome	Very early or very late onset, paroxysmal exertional dyskinesia, low CSF glucose, drug resistance, ketogenic-diet responsiveness
Focal impaired-awareness (temporal/frontal) seizures	Aura, longer duration, post-ictal confusion, focal EEG, structural MRI abnormality
Absence-to-bilateral-tonic-clonic with focal features	See PMID:40347446 (Epileptic Disord 2025) — a genuine diagnostic trap
Non-epileptic staring / daydreaming / inattentive ADHD	Interruptible; no EEG correlate; hyperventilation-negative
Lennox-Gastaut	<2.5 Hz slow spike-wave, abnormal background, intellectual disability, tonic seizures

The StatPearls differential list (benign centrotemporal epilepsy, benign neonatal convulsions, benign occipital paroxysms) is unhelpfully off-target for JAE — I'd not carry it into a dismech entry.

Screening

No population screening exists or is indicated. JAE is polygenic, not amenable to newborn or carrier screening.
Cascade testing is appropriate only in SLC2A1-positive families — where it is genuinely valuable, because unrecognized carriers may have subtle PED or absences and would benefit from a ketogenic diet.

11. Outcome / Prognosis

Survival and mortality

Life expectancy: near-normal. JAE is not a life-shortening disease per se.
SUDEP: the principal disease-attributable mortality risk, driven by GTCS burden. Since 79–95% of JAE patients have GTCS, this is not a trivial concern. ⚠ No JAE-specific SUDEP incidence figure found — gap.
Disease-specific mortality: not quantified for JAE. Additional mortality routes: seizure-related trauma, drowning, status epilepticus.

Seizure outcome — the core prognostic data

Landmark long-term cohort: Trinka E, Baumgartner S, Unterberger I, Unterrainer J, Luef G, Haberlandt E, Bauer G. "Long-term prognosis for childhood and juvenile absence epilepsy." J Neurol 2004;251(10). PMID:15503104, DOI 10.1007/s00415-004-0521-1. - 163 patients, hospital-based, treated 1970–1997, follow-up 1999–2000, mean follow-up ~25.8 years - Seizure-free ≥2 years: CAE 56%, JAE 62%, overlap group 54%; overall remission 58% - Key conclusion: the absence pattern (pyknoleptic vs. non-pyknoleptic) together with later development of additional seizure types predicted long-term outcome better than the CAE/JAE syndrome label itself — a genuinely important nosological finding - Widely cited derived figures: seizure freedom 78% in those with absences only vs. 35% in those with GTCS ⚠ [PARAPHRASE — DO NOT QUOTE]

Contemporary 10-year cohort: Wang X, Zhang X, Wei J, et al. "Long-term seizure outcomes and the likelihood of antiseizure medication withdrawal in patients with juvenile absence epilepsy: A 10-year follow-up study." Seizure 2025. PMID:40945312. - 58 JAE patients, mean onset 11.86 ± 3.87 y, median follow-up 9.57 y - 38 (65.5%) achieved seizure freedom for ≥2 years - ASM withdrawal attempted in 48.3%; 64.3% of those had no recurrence during tapering; ASMs discontinued in 9 patients at last follow-up - Favorable predictor: valproate treatment (independent predictor of seizure freedom) - Unfavorable predictors: total number of GTCS experienced; absence seizures on follow-up EEG; persistence of hyperventilation positivity on EEG - GSWD patterns improved on follow-up EEG in the majority ⚠ [PARAPHRASE — DO NOT QUOTE] — abstract came through a summarizer.

Reported range across the literature: remission rates from 21% to 89% (StatPearls) — the spread reflects wildly different definitions of "remission," cohort ascertainment (tertiary referral vs. population), and follow-up duration. A dismech entry should present the range and name the reason for the spread rather than pick a single number.

Withdrawal and relapse

Older data (StatPearls, ⚠): "All patients with JAE relapsed after AED withdrawal, and 25% of patients continuing on AEDs relapsed" in one study — versus another prospective study where only 3 of 9 seizure-free patients relapsed.
Newer data (PMID:40945312) is considerably more optimistic: ~2/3 of withdrawal attempts succeeded without recurrence.
Practical upshot: JAE is traditionally taught as lifelong-treatment, but the 2025 data suggest withdrawal is viable in a well-selected subgroup. Worth curating as a shifting evidence base, not settled fact.
Related: PMID:39654414 (J Child Neurol 2025) on the need for repeat EEG after ASM withdrawal in pediatric IGE.

Prognostic factors

Factor	Direction
GTCS present / high GTCS count	Worse
Myoclonic seizures	Worse (and prompts JME reclassification)
Anxiety at presentation	Predicts GTCS development (PMID:37461321)
Bifrontal slowing / mild background slowing on initial EEG	Predicts GTCS development (PMID:37461321)
Persistent absences or hyperventilation positivity on follow-up EEG	Worse
Valproate treatment	Better (PMID:40945312) — but see the teratogenicity trade-off
Non-pyknoleptic absence pattern	Prognostically informative independent of syndrome label (PMID:15503104)

Prognostic biomarkers: none molecular. All prognostic markers are clinical/EEG. Genuine gap.

Morbidity, disability, function

Educational: ~2× hazard for special-needs education; lower GPA; 15% fewer attending high school (PMID:35595971)
Psychiatric: anxiety, depression, ADHD, sleep disorder; psychiatric comorbidity ~43% ⚠
Cognitive: deficits in attention, executive function, language — present even without breakthrough seizures ⚠
Social: driving restriction, employment limitation, medication burden, pregnancy-planning constraints
QoL instruments: no JAE-specific EQ-5D/SF-36/PROMIS data — gap

12. Treatment

12.1 First-line pharmacotherapy — and the central dilemma

JAE treatment has a structural problem: the most effective drug is the one you cannot safely give to half the patient population. Most JAE patients are adolescent, and roughly half of them are female and entering reproductive years exactly as treatment begins. Valproate works best and is teratogenic. That tension shapes the entire algorithm.

Drug	Role	Notes
Valproate / valproic acid	First-line for absences and GTCS; independent predictor of seizure freedom	Contraindicated in females of childbearing potential except under a Pregnancy Prevention Programme; contraindicated with POLG variants
Lamotrigine	First-line alternative, preferred in young females	Best JAE-specific evidence in women (below)
Levetiracetam	Widely used first-line, especially in women	Inferior to valproate in SANAD II; inferior to lamotrigine in JAE women (below)
Ethosuximide	Effective for absences only — does not protect against GTCS	Since 79–95% of JAE patients get GTCS, ethosuximide monotherapy is usually inadequate in JAE (unlike CAE, where it's optimal first-line)
Topiramate, zonisamide, perampanel, clobazam, brivaracetam	Second-line / adjunctive	See trial data below

Key trial evidence:

SANAD II (generalised/unclassifiable arm) — Marson A, et al. Lancet 2021;397:1375–1386. In per-protocol analysis, valproate was superior to levetiracetam for both time to 12-month remission and time to treatment failure; the trial "did not support the use of levetiracetam as a first-line treatment for newly diagnosed generalised epilepsy at 12 months." ⚠ verify PMID (likely 33838757) and re-quote.
Glauser CAE trial — ethosuximide and valproate superior to lamotrigine for treatment failure in a 14-week double-blind RCT; ethosuximide the optimal initial monotherapy for childhood absence epilepsy given efficacy + attentional tolerability. ⚠ This is CAE, not JAE — do not import the conclusion wholesale, because the GTCS burden in JAE changes the calculus entirely. (Cochrane update: PMID:28195639.)
JAE-specific, women of childbearing age — the most directly applicable modern evidence: Cerulli Irelli E, Cocchi E, Gesche J, Peña-Ceballos J, Caraballo RH, Lattanzi S, et al. "Lamotrigine vs levetiracetam in female patients of childbearing age with juvenile absence epilepsy: A Bayesian reanalysis." Epilepsia 2024. PMID:39126356. Multicenter; 123 women with JAE, lamotrigine (n=67) vs. levetiracetam (n=56) as initial monotherapy. LTG showed lower treatment failure and higher ASM retention, with a 99.2% posterior probability of LTG superiority for treatment failure; comparable safety profiles. Conclusion supports considering LTG as first-line monotherapy for JAE in women of childbearing age. ⚠ [PARAPHRASE — DO NOT QUOTE] — re-fetch for exact wording.

12.2 Drugs that AGGRAVATE absence seizures — curate this as mechanism, not just a warning

Contraindicated / seizure-aggravating in JAE: carbamazepine, oxcarbazepine, phenytoin, gabapentin, pregabalin, vigabatrin (and tiagabine).

This is not idiosyncratic toxicity — it's the thalamocortical mechanism running in reverse. Sodium-channel blockers and drugs that raise thalamic GABA tone (vigabatrin/tiagabine raise extracellular GABA → more GABA-B-mediated hyperpolarization → more T-type de-inactivation → more burst firing). Giving vigabatrin for absences is like fixing a squeaky hinge by oiling the wrong side of the door.

12.3 Mechanism-directed therapy

Ethosuximide — T-type calcium channel blocker. The one classical ASM whose mechanism maps directly onto §6. Good candidate for a target_mechanisms link to the T-type/burst-firing node.
Valproate — broad-spectrum; T-type modulation + GABAergic + sodium-channel effects
Ketogenic diet — mechanism-directed only in GLUT1 deficiency, where ketone bodies bypass the defective transporter. This is the closest thing JAE has to precision medicine, and it's a strong target_mechanisms candidate against the SLC2A1/glucose-transport node.
Experimental T-type blockers — Tringham et al., Sci Transl Med 2012, PMID:22344687; the CX-8998 program (NCT03406702, absence seizures) represents the translational arm of this mechanism.

12.4 Newer agents and trials

Brivaracetam monotherapy in CAE/JAE — Bast T, et al. "Efficacy and tolerability of brivaracetam monotherapy in childhood and juvenile absence epilepsy: An innovative adaptive trial design." Epilepsia Open 2022. PMID:35844134, DOI 10.1002/epi4.12628. Trial N01269 / NCT04666610, phase 2/3, ages 2–25 with CAE or JAE. Adaptive design: dose-selection/futility stage → interim analysis → optimal-dose stage; each with ≤2-week screening, 2-week placebo-controlled period, 11-week active treatment (10 weeks + 24-h EEG + 1 additional week for 24-h EEG assessment); absence-seizure-free patients enter a ≤4-week randomized withdrawal period. Started July 2021.
Long-term brivaracetam safety extension: NCT06315322
Case-level brivaracetam response in drug-resistant JAE: PMID:40853097 (An Sist Sanit Navar 2025)
Cenobamate — reported in JME (PMID:40042429); JAE evidence not established

12.5 Pharmacogenomics

POLG and valproate — the strongest actionable PGx signal. Valproate is contraindicated in patients with known POLG-related mitochondrial disorders and in children <2 y clinically suspected of mitochondrial disease. Seven POLG1 variants (L304R, A467T, G588D, Q879H, T885S, E1143G, Q1236H) have been associated with valproate-induced liver toxicity. Reported: fatal outcomes in 53/102 (52%) of POLG valproate-exposed patients, all harboring recessive mutations. Mechanism: mitochondrial toxicity via inhibition of beta-oxidation. See NCBI Medical Genetics Summaries NBK620296 and PMID:20138553 ("POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders"). ⚠ figures paraphrased.
HLA-B*15:02 and lamotrigine/carbamazepine — SJS/TEN risk in Southeast Asian ancestry. ⚠ Relevant to lamotrigine dosing decisions; verify current CPIC guidance before curating.
No JAE-specific efficacy pharmacogenomics exists.

12.6 Non-pharmacological

Ketogenic / modified Atkins diet — first-line in GLUT1DS; second-line in drug-resistant absence
Sleep hygiene and trigger avoidance — behavioral, meaningful
Surgery — contraindicated / not applicable. JAE is generalized with no resectable focus. Neuromodulation (VNS/DBS) is not established for JAE.
Genetic counseling — indicated in SLC2A1-positive families and for reproductive planning on valproate

12.7 Adverse events worth curating

Drug	Key AEs
Valproate	Teratogenicity (~10% major congenital malformations; ~30–40% neurodevelopmental disorders, dose-dependent — neural tube defects, hypospadias, cardiac defects, orofacial clefts; reduced IQ, autism, ADHD); weight gain; hepatotoxicity (POLG); pancreatitis; hyperammonemia; PCOS; tremor; alopecia
Lamotrigine	Rash/SJS-TEN (dose-titration dependent); insomnia; oral-contraceptive and pregnancy-related clearance changes requiring level monitoring
Levetiracetam	Behavioral/psychiatric adverse effects (irritability, aggression, depression) — non-trivial in an adolescent population already carrying psychiatric comorbidity
Ethosuximide	GI upset, hiccups, blood dyscrasias, headache; attentional effects milder than valproate
Topiramate	Cognitive slowing, word-finding difficulty, weight loss, nephrolithiasis, teratogenicity

Valproate Pregnancy Prevention Programme: valproate must not be used in females of childbearing potential unless PPP conditions are met — educational program, evaluation/control of therapy, and distribution control. A 2026 joint position statement (Society for Birth Defects Research and Prevention / OTIS / Developmental Neurotoxicology Society) calls for REMS-level risk evaluation and mitigation strategies. ⚠ paraphrased.

12.8 Suggested NCIT treatment terms

Following the dismech treatment_term + therapeutic_agent pattern:

Treatment	`treatment_term` (NCIT)	`therapeutic_agent`	`therapeutic_modality`
Valproate	NCIT:C15986 Pharmacotherapy	CHEBI:39867 `valproic acid` ✓OAK	SMALL_MOLECULE
Ethosuximide	NCIT:C15986	CHEBI:4887 `ethosuximide` ✓OAK	SMALL_MOLECULE
Lamotrigine	NCIT:C15986	CHEBI:6367 `lamotrigine` ✓OAK	SMALL_MOLECULE
Levetiracetam	NCIT:C15986	CHEBI:6437 `levetiracetam` ✓OAK	SMALL_MOLECULE
Brivaracetam	NCIT:C15986	CHEBI:133013 `brivaracetam` ✓OAK	SMALL_MOLECULE
Topiramate	NCIT:C15986	CHEBI:63631 `topiramate` ✓OAK	SMALL_MOLECULE
Zonisamide	NCIT:C15986	CHEBI:10127 `zonisamide` ✓OAK	SMALL_MOLECULE
Perampanel	NCIT:C15986	CHEBI:71013 `perampanel` ✓OAK	SMALL_MOLECULE
Clobazam	NCIT:C15986	CHEBI:31413 `clobazam` ✓OAK	SMALL_MOLECULE
Ketogenic diet	NCIT:C15447 Dietary Intervention ⚠verify	—	BEHAVIORAL
Genetic counseling	NCIT:C15240 Genetic Counseling ⚠verify	—	OTHER

Aggravating drug (for a REFUTE/contraindication evidence item): CHEBI:3387 carbamazepine ✓OAK.

⚠ Per the project memory note on therapeutic_agent: NCIT drug terms often fail therapeutic_agent validation — prefer CHEBI, which is what I've verified above.

12.9 Treatment algorithm sketch

Confirm syndrome (EEG with hyperventilation; exclude JME by ruling out prominent myoclonus)
Consider SLC2A1 testing if early-onset, drug-resistant, PED present, or suggestive family history → if positive, ketogenic diet
Choose first agent by sex and reproductive plans:
Male, or female with no childbearing potential → valproate
Female of childbearing potential → lamotrigine first (PMID:39126356), levetiracetam as alternative
Do not use ethosuximide alone if GTCS have occurred or are likely
Never use carbamazepine/oxcarbazepine/phenytoin/gabapentin/pregabalin/vigabatrin
Address sleep, alcohol, adherence, and psychiatric comorbidity as first-class targets, not afterthoughts
Consider withdrawal only after prolonged seizure freedom with a normalized EEG — and counsel on relapse risk and driving

13. Prevention

Primary prevention

Not possible. JAE is polygenic and constitutional; there is no modifiable exposure to remove. Any "primary prevention" claim in a KB entry would be wrong.

Secondary prevention (early detection)

No population screening. Diagnostic vigilance in an adolescent with unexplained staring, declining school performance, or a first GTCS.
EEG with hyperventilation early in evaluation is the practical "screening" step.
Rapid syndrome assignment matters because the wrong drug (carbamazepine) actively worsens the disease.

Tertiary prevention (preventing complications — where the real action is)

Target	Intervention
GTCS / SUDEP	Optimize ASM adherence; treat GTCS aggressively; nocturnal supervision counseling in high-risk patients
Absence status epilepticus	Recognize prodrome; avoid aggravating drugs; benzodiazepine rescue plans
Injury/drowning	Swimming supervision, bathing precautions, driving restrictions per jurisdiction (PMID:38500008)
Teratogenic harm	Valproate PPP; preconception counseling; high-dose folic acid preconception; switch to lamotrigine/levetiracetam before conception, not after
Hepatotoxicity	POLG testing before valproate in suspicious presentations
Educational/psychiatric harm	Proactive neuropsychological assessment and school support — justified by PMID:35595971
Trigger-driven breakthrough	Sleep hygiene, alcohol moderation, stress management

Immunization

Not applicable as prevention of JAE. General vaccination is appropriate; there is no vaccine-JAE relationship in either direction.

Genetic screening and counseling

Carrier screening / PGD / prenatal testing: not applicable for polygenic JAE
Applicable only in SLC2A1-positive families, where AD inheritance with incomplete penetrance makes cascade testing, counseling, and (rarely) reproductive options meaningful
Empiric recurrence risk counseling for JAE relatives: modestly elevated over population baseline, with a syndrome-shifting caveat (relatives may have JME or GTCA rather than JAE)

Public health / environmental interventions

Not applicable.

14. Other Species / Natural Disease

Naturally occurring absence-like epilepsy

Rat (NCBITaxon:10116): the two flagship strains — GAERS (Genetic Absence Epilepsy Rats from Strasbourg) and WAG/Rij — arose as spontaneous inbred-colony phenotypes, not engineered models. They are arguably the closest thing to "natural disease" in another species, though they exist only in laboratory colonies.
Mouse (NCBITaxon:10090): tottering, lethargic, stargazer, ducky are all spontaneous mutants discovered in mouse colonies — again, natural mutations, laboratory context.
Dog (NCBITaxon:9615): idiopathic epilepsy is the commonest cause of canine seizures, affecting up to ~1% of dogs. A study in Cavalier King Charles Spaniels reported absence seizures with ictal discharges "characterised by generalized onset, 3 to 4 Hz, spike-and-wave complexes" ⚠ — remarkably close to the human phenotype. This is the best candidate for genuine naturally-occurring absence epilepsy in a companion animal. VBO term for Cavalier King Charles Spaniel: ⚠ needs lookup.
Cat (NCBITaxon:9685): idiopathic epilepsy affects up to ~2%; absence-specific phenotypes not well characterized.
OMIA: ⚠ no JAE-specific OMIA entry retrieved in this pass. Worth a direct OMIA query before curating.

Orthologous genes

Human	Mouse ortholog	Relevance
CACNA1H	Cacna1h	GAERS R1584P (rat)
CACNA1A	Cacna1a	tottering, leaner
CACNB4	Cacnb4	lethargic
CACNG2	Cacng2	stargazer
CACNA2D2	Cacna2d2	ducky
SLC2A1	Slc2a1	GLUT1 models

⚠ NCBI Gene IDs not retrieved; look up rather than guess.

Comparative pathology and conservation

The thalamocortical oscillator is deeply conserved across mammals — which is why rodent SWDs look so much like human spike-wave and why ethosuximide suppresses them in both. Key species difference: human absence SWD runs at ~3 Hz; mouse SWD is usually 5–7 Hz. Rat GAERS/WAG-Rij SWDs run ~7–11 Hz. That frequency offset is a real translational caveat and belongs in a HUMAN_MODEL_MISMATCH discussion.

Zoonotic potential / transmission

Not applicable. JAE is genetic and non-transmissible.

15. Model Organisms

15.1 Rat models

GAERS (Genetic Absence Epilepsy Rats from Strasbourg) — the single best-characterized model.

Causal variant: homozygous gain-of-function R1584P substitution in Cacna1h (Cav3.2 T-type Ca²⁺ channel), in exon 24 encoding the proximal III–IV linker (arginine → proline)
Mechanism: the mutation alters the Cav3.2/calnexin interaction, increasing channel surface expression and Ca²⁺ influx — a trafficking mechanism, not a pure gating mechanism. Refs: Sci Rep 2017 (PMC5599688); Neurobiol Dis 2023, PMID:37391087 (R1584P effects in GAERS and NEC congenic rats)
Phenotype: spontaneous behavioral arrest and staring, clonic vibrissal twitching, high-amplitude SWDs
Comparator strain: NEC (Non-Epileptic Control) — an isogenic-ish control, which is methodologically valuable
Genome resource: whole-genome sequence of GAERS and NEC published (PMID:28708842, PLoS One 2017)
Colony variation caveat: PMID:25377760 documents seizure expression, behavior, and brain morphology differences between GAERS colonies — a reproducibility caveat worth curating

WAG/Rij rats — the other flagship strain; the substrate for the cortical focus discovery (Meeren 2002, PMID:11850474), which localized initiation to peri-oral somatosensory cortex.

15.2 Mouse models — the calcium channel subunit quartet

All four spontaneous mutants converge on voltage-dependent calcium channel subunits, exhibit bilaterally synchronous SWDs on cortical EEG with behavioral arrest, and respond to ethosuximide — that last point is the pharmacological validation that makes them credible absence models rather than generic seizure mice.

Model	Gene	Subunit	Notes
tottering (tg)	Cacna1a	Cav2.1 α1A	Also ataxia/dystonia
leaner	Cacna1a	Cav2.1 α1A	More severe allele
lethargic (lh)	Cacnb4	β4
stargazer (stg)	Cacng2	γ2 (also an AMPA-receptor TARP)	Ataxia, head-tossing; NMDA-receptor changes in thalamus (PMC5318904); asynchronous visual-cortex suppression during SWD (Nat Commun 2018)
ducky (du)	Cacna2d2	α2δ-2	Epilepsy + ataxia; decreased Ca²⁺ current in cerebellar Purkinje cells (J Neurosci 2001;21:6095)

Modifier evidence: a targeted Cacng4 mutation exacerbates spike-wave seizures in stargazer mice (PNAS 2005) — a clean demonstration of digenic modification in an absence model.

Engineered models: - Cav3.1 (Cacna1g) knockout mice are resistant to absence seizures — the loss-of-function complement that closes the causal loop on T-type channels - Cav3.1 α1G overexpression produces "pure absence epilepsy": "Genetic Enhancement of Thalamocortical Network Activity by Elevating α1G-Mediated Low-Voltage-Activated Calcium Current Induces Pure Absence Epilepsy," J Neurosci* 2009;29:1615. This bidirectional evidence (KO protects, overexpression causes) is the strongest mechanistic support in the entire field. - Slc2a1/GLUT1 haploinsufficient mice* — model GLUT1DS including seizures and ketogenic-diet responsiveness

15.3 Model characteristics and limitations

What models recapitulate well: - Spontaneous, bilaterally synchronous spike-wave discharges with behavioral arrest - Ethosuximide responsiveness and carbamazepine/vigabatrin aggravation — pharmacological isomorphism - The thalamocortical circuit mechanism and T-type dependence - The GAERS Cacna1h gain-of-function mirrors human CACNA1H gain-of-function susceptibility variants (Heron 2007) — a genuine cross-species convergence

What they do NOT capture (curate as HUMAN_MODEL_MISMATCH, not KNOWLEDGE_GAP): - Frequency mismatch: human 3 Hz vs. mouse 5–7 Hz vs. rat ~7–11 Hz - Age-of-onset structure: rodent models don't reproduce the peripubertal onset window that defines JAE, nor the CAE→JAE age separation - Syndrome specificity: rodent models model absence seizures, not juvenile absence epilepsy. No model reproduces the JAE-specific combination of infrequent absences plus a 79–95% GTCS rate. This is the single biggest translational gap. - Genetic architecture: the models are single-gene, high-penetrance; human JAE is polygenic - Cortical focus: anatomically stereotyped (peri-oral somatosensory) in rat; not demonstrated in human - Comorbidity: rodent models don't model the academic/psychiatric burden that dominates real-world JAE morbidity - Colony drift: GAERS phenotype varies between colonies (PMID:25377760)

15.4 Applications and resources

Applications: ASM screening (ethosuximide-positive controls), T-type blocker development (PMID:22344687, CX-8998), circuit dissection with optogenetics, network-synchrony studies, trafficking/chaperone biology (calnexin/Cav3.2)
Databases: MGI (mouse), RGD (rat), Alliance of Genome Resources, IMSR/JAX for strain availability, IMPC/KOMP for engineered alleles

Curation Notes for the dismech Entry

A few structural suggestions, since this is heading into kb/disorders/Juvenile_Absence_Epilepsy.yaml:

Module conformance — strong candidate: epilepsy_excitation_inhibition_imbalance — the existing module (ion-channel/synaptic dysfunction → excitation/inhibition imbalance → neuronal hyperexcitability and hypersynchrony → seizure generation → recurrent unprovoked seizures) fits JAE almost perfectly. Key conformance target: epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance. JAE would substitute the T-type/GABA-B thalamocortical specifics for the module's generic nodes.

biological_scale tags for pathophysiology nodes: - Variant load / channel gating → MOLECULAR - Thalamic burst firing, nRT/relay-neuron behavior → CELLULAR - Cortico-thalamo-cortical loop entrainment, generalized spike-wave → TISSUE - Absence seizure, absence status, GTCS → ORGANISM

Discussions to include: - KNOWLEDGE_GAP — no molecular/prognostic biomarker; no epigenetic or transcriptomic data; no JAE-specific SUDEP rate; no validated QoL instrument data - HUMAN_MODEL_MISMATCH — SWD frequency offset; absent peripubertal onset window in rodents; rodent cortical focus not demonstrated in humans; single-gene models vs. polygenic human disease - mechanistic_hypotheses — thalamic pacemaker (CANONICAL/legacy) vs. cortical focus (now dominant in models) vs. distributed-network (EMERGING, human imaging)

Evidence-source discipline: - Meeren 2002, GAERS/WAG-Rij, all mouse mutants → MODEL_ORGANISM - Heron 2007 electrophysiology, calnexin trafficking → IN_VITRO - Mendelian-randomization papers (PMIDs 39629734, 39165549, 41443308, etc.) → COMPUTATIONAL, and weight them lightly - Hirsch 2022, Trinka 2004, Boesen 2022, Cerulli Irelli 2024, Wang 2025, Datta 2023, Arsov 2012, Mullen 2010 → HUMAN_CLINICAL

Named-entity-confusion watch: JAE sits squarely in a high-NEC-risk class — it's one of four members of a numbered/named IGE series with heavy phenotypic overlap, and "juvenile absence" vs. "juvenile myoclonic" vs. "childhood absence" are exactly the kind of near-synonym cluster that DR tools blend. If any deep-research report is used, run just preflight-dr <report> MONDO:0800453 first. Also watch for CLCN2 leukoencephalopathy bleeding into the JAE genetics section — different disease, same gene.

The retraction: please do carry the CLCN2 retraction into the entry explicitly. A knowledge base that quietly repeats OMIM's EJA2 entry without the 2009 retraction is propagating a known-false claim, and this is one of the rare cases where dismech can be more correct than its upstream source.

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Progression

Prevalence

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Juvenile Absence Epilepsy — Comprehensive Research Report

⚠️ Read this before you paste anything into YAML

1. Disease Information

Overview

Identifiers

Synonyms

Data provenance character

2. Etiology

Causal architecture in one sentence

Genetic risk factors

Environmental / non-genetic risk factors

Protective factors

Gene–environment interaction

3. Phenotypes

3.1 Absence seizures (the defining feature)

3.2 Generalized tonic-clonic seizures

3.3 Myoclonic seizures

3.4 Absence status epilepticus

3.5 Convulsive status epilepticus

3.6 Cognitive, academic, and psychiatric phenotypes

3.7 Antecedent history

3.8 EEG phenotype (laboratory/electrophysiological)

3.9 Quality-of-life impact

4. Genetic / Molecular Information

4.1 The honest framing

4.2 Named susceptibility genes

4.3 Inheritance / mode

4.4 Allele frequency, somatic/germline, functional consequence

4.5 Modifier genes, epigenetics, chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 The causal chain, upstream to downstream

6.2 The thalamocortical oscillator — the core machinery

6.3 Cortical focus vs. thalamic pacemaker — a real, curatable controversy

6.4 Network-level and human neuroimaging findings

6.5 Metabolic mechanism (the GLUT1 branch)

6.6 Immune, inflammatory, fibrotic, oxidative mechanisms

6.7 Omics

Suggested GO terms (all ✓OAK verified locally)

7. Anatomical Structures Affected

Organ / system level

Structures

Cell types

Subcellular

Lateralization

8. Temporal Development

Onset

The 8–11 year "watershed"

Course and progression

Critical windows

9. Inheritance and Population

Epidemiology

Inheritance

Population demographics

10. Diagnostics

Diagnosis is clinical + electroencephalographic. There is no biomarker.

ILAE 2022 diagnostic criteria (Hirsch 2022, PMID:35503716)

Electrophysiology (the diagnostic centerpiece)

Imaging

Laboratory tests

Genetic testing